MANNATECH INC Form 10-Q November 09, 2006 Table of Contents

September 2006

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

	Washington, D.C. 20549
	FORM 10-Q
(Mark One)	
ACT	RTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 terly period ended: September 30, 2006
	OR
ACT	NSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE OF 1934 sition period from to
	Commission File No. 000-24657
	MANNATECH, INCORPORATED (Exact Name of Registrant as Specified in its Charter)

Table of Contents

75-2508900

(I.R.S. Employer

Texas

(State or other Jurisdiction of

Edgar Filing: MANNATECH INC - Form 10-Q

Incorporation or Organization)

Identification No.)

600 S. Royal Lane, Suite 200

Coppell, Texas 75019

(Address of Principal Executive Offices, including Zip Code)

Registrant s Telephone Number, including Area Code: (972) 471-7400

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No "

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes "No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of accelerated filer or large accelerated filer in Rule 12b-2 of the Exchange Act.

Large accelerated filer " Accelerated filer x Non-accelerated filer "

As of October 31, 2006, the number of shares outstanding of the registrant s sole class of common stock, par value \$0.0001 per share, was 26,401,654.

Mannatech, Incorporated

TABLE OF CONTENTS

		Page
	NANCIAL INFORMATION	í
Item 1.	Financial Statements	1
	Consolidated Balance Sheets Unaudited	1
	Consolidated Statements of Operations Unaudited	2
	Consolidated Statements of Changes in Shareholders Equity - Unaudited	3
	Consolidated Statements of Cash Flows Unaudited Notes to Unaudited Consolidated Financial Statements	5
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	19
	Company Overview	19
	Critical Accounting Policies and Estimates	20
	Results of Operations	22
	Three and Nine Months Ended September 30, 2006 Compared with the Same Periods in 2005	23
	Liquidity and Capital Resources	32
	Recent Accounting Pronouncements	34
	Forward-Looking Statements	35
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	37
Item 4.	Controls and Procedures	38
Part II <u>O</u>	THER INFORMATION	
Item 1.	<u>Legal Proceedings</u>	38
Item 1A.	Risk Factors	40
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	41
Item 3.	<u>Defaults Upon Senior Securities</u>	41
Item 4.	Submission of Matters to a Vote of Security Holders	41
Item 5.	Other Information	41
Item 6.	<u>Exhibits</u>	42
Signatur	<u>es</u>	43

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

MANNATECH, INCORPORATED

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

	Dec	cember 31,	Sep	tember 30,
		2005	(u	2006 naudited)
ASSETS				
Cash and cash equivalents	\$	56,207	\$	39,943
Short-term investments		1,974		
Restricted cash		2,777		3,129
Accounts receivable		548		1,442
Income tax receivable				809
Inventories, net		19,811		20,145
Prepaid expenses and other current assets		3,471		4,052
Deferred tax assets		671		628
Note receivable from affiliate		153		160
Total current assets		85,612		70,308
Long-term investments		15,375		25,375
Property and equipment, net		10,951		14,961
Construction in progress		8,157		21,175
Long-term restricted cash		1,476		2,191
Other assets		1,121		1,450
Long-term deferred tax assets		103		144
Total assets	\$	122,795	\$	135,604
LIABILITIES AND SHAREHOLDERS EQUITY				
Current portion of capital lease	\$	23	\$	76
Accounts payable		5,476		4,742
Accrued expenses		16,941		16,584
Commissions and incentives payable		15,588		13,414
Taxes payable		5,773		1,865
Deferred revenue		3,712		3,954
Current deferred tax liabilities				184
Total current liabilities		47,513		40,819
Capital lease, excluding current portion				302
Long-term royalties due to an affiliate		3,341		2,990
Long-term deferred tax liabilities		1,086		6,155
Long-term liabilities		537		630
Total liabilities		52,477		50,896
Commitments and contingencies				

Shareholders equity:

Edgar Filing: MANNATECH INC - Form 10-Q

Preferred stock, \$0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding		
Common stock, \$0.0001 par value, 99,000,000 shares authorized, 27,404,513 shares issued and		
26,738,364 shares outstanding in 2005 and 27,607,081 shares issued and 26,399,987 shares outstanding		
in 2006	3	3
Additional paid-in capital	36,699	38,650
Retained earnings	42,505	62,459
Accumulated other comprehensive loss	(1,098)	(1,613)
	78,109	99,499
Less treasury stock, at cost, 666,149 shares in 2005 and 1,207,094 in 2006	(7,791)	(14,791)
Total shareholders equity	70,318	84,708
ı v	, -	,
Total liabilities and shareholders equity	\$ 122,795	\$ 135,604

 $See\ accompanying\ notes\ to\ unaudited\ consolidated\ financial\ statements.$

MANNATECH, INCORPORATED

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(in thousands, except per share information)

	Three months ended September 30, 2005 2006			1	nded 30, 2006			
Net sales	\$	100,216	\$ 9	99,558	\$ 2	87,960	\$ 3	303,300
Cost of sales		14,478		13,497		43,186		42,777
Commissions and incentives		44,403		43,977		29,326		135,349
		58,881		57,474		72,512		178,126
Gross profit		41,335	4	42,084	1	15,448	1	125,174
Operating expenses:								
Selling and administrative expenses		16,136		16,562		48,595		52,569
Other operating costs		12,415		14,051		36,587		39,724
Total operating expenses		28,551	3	30,613		85,182		92,293
Income from operations		12,784	1	11,471		30,266		32,881
Interest income		469		599		1,254		1,763
Other income (expense), net		(288)		670		(1,188)		805
Income before income taxes		12,965	1	12,740		30,332		35,449
Provision for income taxes		(4,232)		(3,052)	(11,120)		(11,241)
Net income	\$	8,733	\$	9,688	\$	19,212	\$	24,208
Earnings per share:								
Basic	\$	0.32	\$	0.37	\$	0.71	\$	0.91
Diluted	\$	0.32	\$	0.36	\$	0.69	\$	0.89
Weighted-average common shares outstanding:								
Basic		27,015	2	26,446		27,065		26,663
Diluted		27,738	2	27,044		27,899		27,280

See accompanying notes to unaudited consolidated financial statements.

MANNATECH, INCORPORATED

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (UNAUDITED)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2005 and 2006

(in thousands, except per share information)

	Comm						Accur	nulated	Treas	ury stock		
				Ad	ditional		01	her				Total
	Issued			p	aid in	Retained	compr	ehensive			sha	reholders
	_	Par						<i>a</i> \	G.			
Balance at December 31, 2004	shares 27,115	valu \$:			apital 34,917	earnings \$ 21,672	\$	ne (loss) 195	Shares 74	Amounts \$ (562)	\$	equity 56,225
Proceeds from stock options exercised	258	Ψ.		Ψ	556	Ψ 21,072	Ψ	175	, .	ψ (302)	Ψ	556
Tax benefit from exercise of stock options					807							807
Tender of common stock to exercise stock												
options					231				12	(231)		
Benefit related to stock options and warrants					(95)							(95)
Repurchase of common stock									373	(4,998)		(4,998)
Declared dividends of \$0.14 per share						(5,672)						(5,672)
Components of comprehensive income:												
Foreign currency translation								(988)				(988)
Unrealized gain from investments classified as												
available for sale, net of tax of \$8								5				5
Net income						19,212						19,212
Total comprehensive income												18,229
Balance at September 30, 2005	27,373	\$ 3	3	\$	36,416	\$ 35,212	\$	(788)	459	\$ (5,791)	\$	65,052
	~											
	Comn Stoc						Accui	nulated	Treas	ury stock		
	Stoc	.11					O	her	11003	ary stock		Total
	Issued			Δd	ditional		compr	ehensive			sha	reholders
		Par			aid in	Retained						
	Shares	valu	e	c	apital	earnings	incon	ne (loss)	Shares	Amounts		equity
Balance at December 31, 2005	27,404	\$ 3	3	\$	36,699	\$ 42,505	\$	(1,098)	666	\$ (7,791)	\$	70,318
Proceeds from stock options exercised	203				942							942
												52
Tax benefit from exercise of stock options					52							_
Tax benefit from exercise of stock options Charge related to stock-based compensation					52 471							471
Charge related to stock-based compensation Benefit related to stock options and warrants					_							471 486
Charge related to stock-based compensation Benefit related to stock options and warrants Repurchase of common stock					471				541	(7,000)		471 486 (7,000)
Charge related to stock-based compensation Benefit related to stock options and warrants Repurchase of common stock Declared dividends of \$0.16 per share					471	(4,254)			541	(7,000)		471 486
Charge related to stock-based compensation Benefit related to stock options and warrants Repurchase of common stock					471	(4,254)			541	(7,000)		471 486 (7,000)
Charge related to stock-based compensation Benefit related to stock options and warrants Repurchase of common stock Declared dividends of \$0.16 per share Components of comprehensive income:					471	(4,254)		(530)	541	(7,000)		471 486 (7,000) (4,254)
Charge related to stock-based compensation Benefit related to stock options and warrants Repurchase of common stock Declared dividends of \$0.16 per share					471	(4,254)		(530) 15	541	(7,000)		471 486 (7,000)

Edgar Filing: MANNATECH INC - Form 10-Q

Unrealized loss from investments classified as available for sale, net of tax of \$9								
Net income				24,208				24,208
Total comprehensive income								23,693
Balance at September 30, 2006	27,607	\$ 3	\$ 38,650	\$ 62,459	\$ (1,613)	1,207	\$ (14,791)	\$ 84,708

See accompanying notes to unaudited consolidated financial statements.

MANNATECH, INCORPORATED

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(in thousands)

Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)		Nine mont Septemb 2005	
Adjustments to reconcile net income to net cash provided by operating activities: 2,846 3,542 Depreciation and amortization 2,7 202 Loss on disposal of assets 43 128 Azx benefit from exercise of stock options 80 Accounting charge related to stock options and warrants granted 95 52 Accounting charge related to stock obstack asset compensation expense 41 525 Deferred income taxes 1,37 5,256 Accrued interest on note receivable 662 9(10) Increase in accounts receivable 660 9(10) Increase in income tax receivable 660 9(10) Increase in morn tax receivable 660 9(10) Increase in recent expenses and other current assets 660 9(10) Increase in prepaid expenses and other current assets 660 9(10) Increase in decrease in other assets 4 308 Increase (decrease) in accounts payable 6,925 45,73 Increase in decrease in other assets 4 4 308 Increase in decrease in other assets 4 <th>CASH FLOWS FROM OPERATING ACTIVITIES:</th> <th></th> <th></th>	CASH FLOWS FROM OPERATING ACTIVITIES:		
Depreciation and amortization 2,846 3,542 Write-down of inventories 27 202 202 Loss on disposal of assets 43 128 Tax benefit from exercise of stock options 807	Net income	\$ 19,212	\$ 24,208
Write-down of inventories 27 202 Loss on disposal of assets 43 128 Tax benefit from exercise of stock options 807 Accounting charge related to stock-options and warrants granted 95 52 Accounting charge related to stock-obsed compensation expense 1,377 5,256 Accrued interest on note receivable (602) 910 Increase in accounts receivable (602) 910 Increase in income tax receivable (609) 180 Increase in income tax receivable (629) (809) Increase in income tax receivable (629) (809) Increase in income tax receivable (629) (809) Increase in decrease in other sasets (629) (858) Increase (decrease in other assets (4 (308) Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in commissions and incentives payable 9,25 (457) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 2,507 24 Cashistion of prop			
Loss on disposal of assets 43 128 Tax benefit from exercise of stock options 807 Accounting charge related to stock options and warrants granted 95 52 Accounting charge related to stock-based compensation expense 1,37 5,256 Deferred income taxes 1,37 5,256 Accrued interest on note receivable (7 (7) Changes in operating assets and liabilities: Increase in accounts receivable (662) (910) Increase in income tax receivable (662) (809) Increase in income tax receivable (7,354) (588) Increase in inventories (7,354) (580) Increase in inventories (7,354) (587) Increase in inventories and other current assets 4 (308) Increase of decrease in other assets 4 (308) Increase in decrease in accounts payable 6,925 (4,573) Increase (decrease) in accounts payable 9,14 (2,198) Increase in deferred revenue 2,760 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 18 <t< td=""><td></td><td>2,846</td><td></td></t<>		2,846	
Tax benefit from exercise of stock options 807 Accounting charge related to stock options and warrants granted 95 Accounting charge related to stock-based compensation expense 1,377 5,256 Accrued interest on note receivable (7) 70 Changes in operating assets and liabilities: 809 1,809 Increase in accounts receivable (602) 910 Increase in inventories (629) (587) Increase in inventories (629) (587) Increase in prepaid expenses and other current assets (629) (587) Increase (decrease in other assets (629) (587) Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in accounts payable 2,507 242 Net cash provided by operating activities 27,606 23,415 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 2 1 Decrease in restricted cash 1,61 2,629 Druchas		27	202
Accounting charge related to stock options and warrants granted 95 52 Accounting charge related to stock options and warrants granted 471 Deferred income taxes 1,377 5,256 Accrued interest on note receivable (62) (7) (7) Changes in operating assets and liabilities: (662) (910) Increase in income tax receivable (809) (587) Increase in income tax receivable (629) (587) Increase in income tax receivable (629) (587) Increase in inventories (629) (587) Increase in prepaid expenses and other current assets (629) (587) Increase in inventories (629) (587) Increase decrease in other assets 4 (308) Increase (decrease) in accrust payable 1,691 (736) Increase (decrease) in accrust payable 914 (2,198) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 18 Decrease in rest		43	128
Accounting charge related to stock-based compensation expense 471 5,256 Accrued interest on note receivable (7) (7) Changes in operating assets and liabilities: 8(80) (90) Increase in accounts receivable (809) (809) Increase in inventories (7,354) (558) Increase in prepaid expenses and other current assets (629) (887) Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in accound expenses and taxes payable 1,91 (2,198) Increase (decrease) in accound sepanses and incentives payable 914 (2,198) Increase (decrease) in accound expenses and incentives payable 914 (2,198) Increase (decrease) in commissions and incentives payable 914 (2,198) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASHILOWS FROM INVESTING ACTIVITIES: 18 Decrease in restricted cash (2,467) 9(60) Proceeds from sale of assets 18 Decrease in restricted cash (2,457)	Tax benefit from exercise of stock options	807	
Deferred income taxes 1,377 5,256 Accrued interest on note receivable (7) (7) Changes in operating assets and liabilities: (662) (910) Increase in accounts receivable (809) (871) Increase in income tax receivable (629) (587) Increase in inventories (629) (587) Increase in operatid expenses and other current assets (629) (587) (Increase) decrease in other assets 4 (308) Increase decrease in in outsuits payable (629) (4,573) Increase (decrease) in accrued expenses and taxes payable (6,925) (4,573) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 2 2 (2,242) (2,285) Proceeds from sale of assets 18 18 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 <		(95)	52
Accrued interest on note receivable (7) (7) Changes in operating assets and liabilities: (662) 9101 Increase in accounts receivable (809) (809) Increase in inventories (7,354) (558) Increase in prepaid expenses and other current assets (629) (587) Increase in prepaid expenses and other current assets 4 (308) (308) Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in accrued expenses and taxes payable 6,925 (4,573) Increase (decrease) in accrued expenses and incentives payable 914 (2,198) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 8 18 Decrease in restricted cash 347 16 Increase in restricted cash 347 16 Increase in restricted cash 2,461 966) Purchase of investments (2,461) 966) Purchase of investments (1,621) (29,246)			
Changes in operating assets and liabilities: Increase in accounts receivable (662) (910) Increase in income tax receivable (809) (809) Increase in inventories (7,354) (558) Increase in prepaid expenses and other current assets (629) (587) (Increase) decrease in other assets (629) (587) Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in accounts payable 6,925 (4,573) Increase (decrease) in accounts payable 914 (2,198) Increase (decrease) in commissions and incentives payable 914 (2,198) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 4 (9,242) (20,285) Proceeds from sale of assets 9 18 Decrease in restricted cash (2,467) (966) Purchase of investments (2,467) (966) Purchase of investments (1,621) (29,46) CASH FLOWS FROM FINANCING ACTIVITIES:	Deferred income taxes	1,377	5,256
Increase in accounts receivable (802) Increase in income tax receivable (7,354) Increase in income tax receivable (558) Increase in prepaid expenses and other current assets (629) (587) (Increase) decrease in other assets 4 (308) Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in accrued expenses and taxes payable 914 (2,198) Increase (decrease) in commissions and incentives payable 914 (2,198) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 8 18 Acquisition of property and equipment (9,242) (20,285) Proceeds from sale of assets 18 18 Decrease in restricted cash 347 18 Increase in restricted cash (2,467) (966) Purchase of investments (29,246) (29,246) Recash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: 18 486	Accrued interest on note receivable	(7)	(7)
Increase in income tax receivable (809) Increase in inventories (7,354) (558) Increase in inventories (629) (587) Increase in prepaid expenses and other current assets 4 (308) Increase (decrease) in accounts payable 1,691 (7354) Increase (decrease) in accounts payable 6,925 (4,573) Increase (decrease) in commissions and incentives payable 914 (2,198) Increase (decrease) in commissions and incentives payable 914 (2,198) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASHFLOWS FROM INVESTING ACTIVITIES: 8 18 Proceeds from sale of assets 18 18 Proceeds from sale of assets 18 18 Proceeds from sale of assets 2,467 (9,66) Purchase of investments (2,467) (9,66) Purchase of investments (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: 1 1,624 Tax benefit from exercise of stock options	Changes in operating assets and liabilities:		
Increase in inventories (7,354) (558) Increase in prepaid expenses and other current assets (629) (587) Increase (decrease in other assets 4 (308) Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in accrued expenses and taxes payable 6,925 (4,573) Increase (decrease) in commissions and incentives payable 2,507 242 Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 2 Acquisition of property and equipment (9,242) (20,285) Proceeds from sale of assets 18 Decrease in restricted cash 2,467 (966) Purchase of investments (2,467) (966) Purchase of investing activities (1,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: 347 Tax benefit from exercise of stock options 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cas	Increase in accounts receivable	(662)	(910)
Increase in prepaid expenses and other current assets (629) (587) (Increase) decrease in other assets 4 (308) Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in accounts payable 6,925 (4,573) Increase (decrease) in accounts payable 914 (2,198) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 2 (20,285) Proceeds from sale of assets 18 18 Decrease in restricted cash 347 18 Decrease in restricted cash 347 19 (2,467) (966) Purchase of investments (2,467) (966) (960) Purchase of investments (2,59) (8,013) Net cash used in investing activities (1,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: 2 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) <	Increase in income tax receivable		(809)
(Increase) decrease in other assets 4 (308) Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in accounts payable 6,925 (4,573) Increase (decrease) in commissions and incentives payable 914 (2,198) Increase (decrease) in commissions and incentives payable 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 2 Acquisition of property and equipment (9,242) (20,285) Proceeds from sale of assets 18 Decrease in restricted cash 347 Increase in restricted cash (2,467) (966) Purchase of investments (259) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: 486 Tax benefit from exercise of stock options 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 (4254) Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) <td< td=""><td>Increase in inventories</td><td>(7,354)</td><td>(558)</td></td<>	Increase in inventories	(7,354)	(558)
Increase (decrease) in accounts payable 1,691 (736) Increase (decrease) in accrued expenses and taxes payable 6,925 (4,573) Increase (decrease) in commissions and incentives payable 914 (2,198) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: State of the property and equipment (9,242) (20,285) Proceeds from sale of assets 18 18 Decrease in restricted cash 347 18 Increase in restricted cash (2,467) (966) Purchase of investments (2,59) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: Tax benefit from exercise of stock options 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activitie	Increase in prepaid expenses and other current assets	(629)	(587)
Increase (decrease) in accrued expenses and taxes payable 6,925 (4,573) Increase (decrease) in commissions and incentives payable 914 (2,198) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: Sequisition of property and equipment (9,242) (20,285) Proceeds from sale of assets 18 Decrease in restricted cash 347 Increase in restricted cash (2,467) (966) Purchase of investments (259) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: ** Tax benefit from exercise of stock options 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (4,947) (16,264)	(Increase) decrease in other assets	4	(308)
Increase (decrease) in commissions and incentives payable 914 (2,198) Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 8 Acquisition of property and equipment (9,242) (20,285) Proceeds from sale of assets 18 Decrease in restricted cash 347 Increase in restricted cash (2,467) (966) Purchase of investments (259) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 (942) Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (4,947) (16,264) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	Increase (decrease) in accounts payable	1,691	(736)
Increase in deferred revenue 2,507 242 Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: 2 Acquisition of property and equipment (9,242) (20,285) Proceeds from sale of assets 18 Decrease in restricted cash 347 (966) Purchase of investments (2,467) (966) Purchase of investments (259) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: 346 347 346 Repurchase of common stock (4,998) (7,000) 346 <td>Increase (decrease) in accrued expenses and taxes payable</td> <td>6,925</td> <td>(4,573)</td>	Increase (decrease) in accrued expenses and taxes payable	6,925	(4,573)
Net cash provided by operating activities 27,606 23,415 CASH FLOWS FROM INVESTING ACTIVITIES: X Counsistion of property and equipment (9,242) (20,285) Proceeds from sale of assets 18 18 Decrease in restricted cash 347 1 Increase in restricted cash (2,467) (966) Purchase of investments (259) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: Tax benefit from exercise of stock options 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	Increase (decrease) in commissions and incentives payable	914	(2,198)
CASH FLOWS FROM INVESTING ACTIVITIES: Acquisition of property and equipment (9,242) (20,285) Proceeds from sale of assets 18 Decrease in restricted cash 347 Increase in restricted cash (2,467) (966) Purchase of investments (259) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: ** Tax benefit from exercise of stock options 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	Increase in deferred revenue	2,507	242
Acquisition of property and equipment (9,242) (20,285) Proceeds from sale of assets 18 Decrease in restricted cash 347 Increase in restricted cash (2,467) (966) Purchase of investments (259) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: Tax benefit from exercise of stock options 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	Net cash provided by operating activities	27,606	23,415
Proceeds from sale of assets 18 Decrease in restricted cash 347 Increase in restricted cash (2,467) (966) Purchase of investments (259) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: *** *** Tax benefit from exercise of stock options 486 (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	CASH FLOWS FROM INVESTING ACTIVITIES:		
Decrease in restricted cash 347 Increase in restricted cash (2,467) (966) Purchase of investments (259) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: *** *** Tax benefit from exercise of stock options 486 (7,000) Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	Acquisition of property and equipment	(9,242)	(20,285)
Increase in restricted cash Purchase of investments (2,467) (966) Purchase of investments (259) (8,013) Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Tax benefit from exercise of stock options Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised Froceeds from stock options exercised Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents 4,817 (16,264)	Proceeds from sale of assets		18
Purchase of investments (259) (8,013) Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: Tax benefit from exercise of stock options 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	Decrease in restricted cash	347	
Net cash used in investing activities (11,621) (29,246) CASH FLOWS FROM FINANCING ACTIVITIES: Tax benefit from exercise of stock options 486 Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	Increase in restricted cash	(2,467)	(966)
CASH FLOWS FROM FINANCING ACTIVITIES:Tax benefit from exercise of stock options486Repurchase of common stock(4,998)(7,000)Payment of cash dividends(5,672)(4,254)Proceeds from stock options exercised556942Repayment of capital lease obligation(7)(59)Net cash used in financing activities(10,121)(9,885)Effect of exchange rate changes on cash and cash equivalents(1,047)(548)Net increase (decrease) in cash and cash equivalents4,817(16,264)	Purchase of investments	(259)	(8,013)
CASH FLOWS FROM FINANCING ACTIVITIES:Tax benefit from exercise of stock options486Repurchase of common stock(4,998)(7,000)Payment of cash dividends(5,672)(4,254)Proceeds from stock options exercised556942Repayment of capital lease obligation(7)(59)Net cash used in financing activities(10,121)(9,885)Effect of exchange rate changes on cash and cash equivalents(1,047)(548)Net increase (decrease) in cash and cash equivalents4,817(16,264)	Net cash used in investing activities	(11,621)	(29,246)
Tax benefit from exercise of stock options486Repurchase of common stock(4,998)(7,000)Payment of cash dividends(5,672)(4,254)Proceeds from stock options exercised556942Repayment of capital lease obligation(7)(59)Net cash used in financing activities(10,121)(9,885)Effect of exchange rate changes on cash and cash equivalents(1,047)(548)Net increase (decrease) in cash and cash equivalents4,817(16,264)	_		•
Repurchase of common stock (4,998) (7,000) Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)			186
Payment of cash dividends (5,672) (4,254) Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)		(4 908)	
Proceeds from stock options exercised 556 942 Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)			
Repayment of capital lease obligation (7) (59) Net cash used in financing activities (10,121) (9,885) Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	·		
Effect of exchange rate changes on cash and cash equivalents (1,047) (548) Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	*		
Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	Net cash used in financing activities	(10,121)	(9,885)
Net increase (decrease) in cash and cash equivalents 4,817 (16,264)	Effect of exchange rate changes on cash and cash equivalents	(1 047)	(548)
	2.1000 of oronange rate enanges on easi and easi equivalents	(1,047)	(370)
	Net increase (decrease) in cash and cash equivalents	4,817	(16,264)
	Cash and cash equivalents at the beginning of period	44,198	56,207

Edgar Filing: MANNATECH INC - Form 10-Q

Cash and cash equivalents at the end of period	\$ 4	19,015	\$ 3	9,943
SUMMARY OF NON-CASH INVESTING AND FINANCING ACTIVITIES:				
Declaration of dividends	\$	1,885	\$	
Unrealized losses from investments	\$		\$	24
Treasury shares tendered to exercise stock options	\$	231	\$	
Purchase of fixed assets through capital lease	\$		\$	414

See accompanying notes to unaudited consolidated financial statements.

MANNATECH, INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Mannatech, Incorporated (the Company), located in Coppell, Texas, was incorporated in the state of Texas on November 4, 1993 and is listed on the NASDAQ Global Select National Market under the symbol MTEX . The Company develops high-quality, proprietary, nutritional supplements, skin care and topical products, and weight-management products that are primarily sold to independent associates and members located in the United States, Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, and Germany.

Independent associates (associates) purchase the Company s products at published wholesale prices for the primary purpose of personal consumption and/or sale to retail customers. Members (members) purchase the Company s products at a discount from published retail prices primarily for personal consumption. The Company cannot distinguish its personal consumption sales from its other sales because it has no involvement in its products after delivery other than usual and customary product returns. Only independent associates are eligible to earn commissions and incentives. The Company has thirteen wholly-owned subsidiaries; however, only the following subsidiaries are currently active:

Wholly-owned subsidiary name	Date incorporated	Location of subsidiary	Date operations began
Mannatech Australia Pty Limited	April 1998	St. Leonards, Australia	October 1998
Mannatech Limited	November 1998	Didcot, Oxfordshire, United Kingdom	November 1999
Mannatech Japan, Inc.	January 2000	Tokyo, Japan	June 2000
Mannatech Korea Ltd.	February 2004	Seoul, Republic of Korea	September 2004
Mannatech Taiwan Corporation	June 2004	Coppell, Texas*	June 2005
Mannatech (International) Limited	December 2005	Gibraltar	December 2005

^{*} Mannatech Taiwan Corporation operates a branch office in Taipei, Taiwan.

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with instructions for Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, the Company s consolidated financial statements and footnotes contained herein do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America to be considered complete financial statements. However, in the opinion of the Company s management, the accompanying unaudited consolidated financial statements and footnotes contain all adjustments, including normal recurring adjustments, considered necessary for a fair statement of the Company s consolidated financial information as of, and for, the periods presented. The Company cautions that its consolidated results of operations for an interim period are not necessarily indicative of its consolidated results of operations to be expected for its fiscal year. For further information, refer to the Company s consolidated financial statements and accompanying footnotes included in its annual report on Form 10-K for the year ended December 31, 2005 and filed with the United States Securities and Exchange Commission on March 16, 2006.

Principles of Consolidation

The Company s consolidated financial statements and footnotes include the accounts of the Company and all of its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents

The Company considers all highly liquid investments, including credit card receivables, with original maturities of three months or less to be cash equivalents.

For the year ended December 31, 2005 and the nine months ended September 30, 2006, the Company included in its cash and cash equivalents credit card receivables due from its credit card processor of \$3.0 million and \$2.7 million, respectively, as credit card receivables are received within 24 to 72 hours after receiving the approval code from the credit card processor.

Revenue Recognition

The Company s revenues are primarily derived from sales of its products, sales of its starter and renewal packs, and shipping fees. Substantially all of the Company s product sales are sold to independent associates at published wholesale prices and to members at discounted published retail prices. The Company recognizes revenue upon receipt of packs and products, by its customers. The Company records a reserve for expected sales refunds based on its historical experience.

The Company defers certain of its revenue. Total deferred revenue consists of i) revenue received from sales of products and packs, which were shipped but not received by the customers by period end; ii) revenue received related to prepaid registration fees from customers planning to attend a future corporate-sponsored event; iii) revenue received related to a one-year magazine subscription; and iv) revenue received from pack sales when the pack sale price exceeds the wholesale value of all individual components within the pack. The Company recognizes deferred revenue related to shipped products and packs upon receipt by the customer. All other deferred revenue is recognized over one year. Components of deferred revenue are as follows:

	December 31, 2005	September 30, 2006
Revenue related to undelivered packs and products	\$2.6 million	\$3.3 million
Revenue related to one-year magazine subscription and pack sales exceeding the aggregate wholesale value of individual components sold	0.7 million	0.6 million
Revenue related to future corporate-sponsored events	0.4 million	0.1 million
Total deferred revenue	\$3.7 million	\$4.0 million

Shipping and Handling Costs

The Company records freight and shipping fees collected from its customers as revenue. The Company records inbound freight as cost of sales and records shipping and handling costs associated with shipping products to its customers as selling and administrative expenses. Total shipping and handling costs included in selling and administrative expenses were approximately \$4.7 million and \$4.5 million for the three months ended September 30, 2005 and 2006, respectively. Total shipping and handling costs included in selling and administrative expenses were approximately \$13.7 million and \$13.8 million for the nine months ended September 30, 2005 and 2006, respectively.

NOTE 2 SHAREHOLDERS EQUITY

On June 30, 2004, the Company s Board of Directors authorized the Company to repurchase, in the open market, up to 5% of its outstanding shares, or approximately 1.3 million shares, of its common stock to help manage any dilutive effects of its common stock in the open market. On August 28, 2006, a second program permitting the Company to purchase, in the open market, up to \$20 million of its outstanding shares was approved by its Board of Directors. As of September 30, 2006, the Company had repurchased the following number of shares of its common stock in the open market:

	Number of common shares	Approximate		
Date purchased	purchased in the open market	cost	,	ge price paid er share
May 2005	190,850	\$ 3.0 million	\$	15.71
September 2005	182,626	2.0 million	\$	10.95
October 2005	207,023	2.0 million	\$	9.66
May 2006	73,955	1.0 million	\$	13.52
June 2006	253,289	3.0 million	\$	11.84

Edgar Filing: MANNATECH INC - Form 10-Q

Total	1,121,444	\$ 14.0 million	\$ 12.48
August 2006	68,861	1.0 million	\$ 14.52
July 2006	144,840	2.0 million	\$ 13.81

As of September 30, 2006, the maximum number of shares available for repurchase under the June 2004 plan, previously approved by the Company s Board of Directors, was 196,124. The Company is also authorized to purchase up to \$20 million of its outstanding shares, in the open market, under its August 2006 plan.

Accounting for Stock-Based Compensation

The Company has three stock-based compensation plans, all of which were approved by its shareholders. The Company generally grants stock options to its employees and board members at the fair market value of its common stock on the date of grant with a term no greater than ten years. The stock options generally vest over two or three years. Shareholders who own 10% or more of the Company s outstanding stock are granted stock options at an exercise price that may not be less than 110% of the fair market value of the Company s common stock on the date of grant, have a term no greater than five years, and vest over two or three years.

Prior to January 1, 2006, the Company applied disclosure-only provisions of Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation , (FAS 123). In accordance with the provisions of FAS 123, the Company continued to account for stock options granted to its employees and Board of Directors using the recognition and measurement provisions of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and its related interpretations, (APB 25) and accordingly did not recognize compensation expense for stock options issued to employees and board members. For disclosure purposes, the Company used the Black-Scholes option pricing model to calculate the related compensation expense for stock options granted, as if it had applied the fair value recognition provisions of FAS 123. The following table illustrates the effect on the Company s consolidated net income and earnings per share if the Company had applied the fair value recognition provisions of FAS 123 and Statement of Financial Accounting Standards No. 123R, Share-Based Payments, (FAS 123R) retroactively to all of its outstanding stock options for the three and nine months ended September 30, 2005:

	For the three months	For the nine month		
	ended September 30, 2005 (in thousands, excep	•	otember 30, 2005 e information)	
Consolidated net income as reported	\$ 8,733	\$	19,212	
Add: Stock-based employee compensation expense included in reported net income, net of related tax effect of \$37 for both the three months and nine				
months ended September 30, 2005, respectively.	(59)		(59)	
Deduct: Total stock-based employee compensation expense determined under fair value based method for all stock options and warrants, net of related tax effect of \$109 and \$270 for the three and nine months ended September 30,				
2005, respectively.	(178)		(441)	
Pro forma consolidated net income	\$ 8,496	\$	18,712	
Basic Earnings Per Share:				
As reported	\$ 0.32	\$	0.71	
Pro forma	\$ 0.32	\$	0.69	
Diluted Earnings Per Share:				
As reported	\$ 0.32	\$	0.69	
Pro forma	\$ 0.31	\$	0.67	

Effective January 1, 2006, the Company adopted FAS 123R and selected the modified prospective method to initially report all of its related stock-based compensation expense in its consolidated financial statements. Under the modified prospective method, the Company was not required to restate its prior periods—consolidated financial statements, but was required to estimate and disclose the fair value for all of its previously issued and outstanding stock options granted to employees and board members using a fair-value based option-pricing model.

Under the provisions of FAS 123R, the Company is also required to measure and recognize compensation expense related to any outstanding and unvested stock options previously granted, and thereafter recognize, in its consolidated financial statements, compensation expense related to any outstanding and new stock options granted using a calculated fair-value based option-pricing model. The Company uses the Black-Scholes option-pricing model to measure the fair value of all of its stock options.

The Company granted 86,757 stock options for the first nine months of 2005. For the first nine months of 2006, the Company granted 150,158 stock options to its employees and board members as follows:

On January 4, 2006, the Company granted 25,000 stock options to board member Larry Jobe at an exercise price of \$12.23 per share. One-third of the stock options vest immediately and the remainder vest over two years. The options have a term of ten years.

On June 12, 2006, the Company granted 11,150 stock options each to board members Ray Robbins and Gerald Gilbert at an exercise price of \$11.21 per share, and board member Larry Jobe was granted 1,858 stock options at an exercise price of \$11.21 per share. One-third of the stock options vest immediately, and the remainder vest over two years. The options have a term of ten years.

On June 12, 2006, the Company also granted Robert Panico, Vice President of Global Human Resources, and Gary Spinell, Vice President of Treasury and Investor Relations, 20,000 stock options each at an exercise price of \$11.21 per share. These options vest over three years and have a term of ten years.

On June 27, 2006, the Company granted Terence O Day, Executive Vice President of Global Operations, 25,000 stock options at an exercise price of \$11.16 per share. These options vest over three years and have a term of ten years.

On August 7, 2006, the Company granted Mr. O Day, 6,000 additional stock options at an exercise price of \$14.16 per share. These options vest over three years and have a term of ten years.

On August 28, 2006, the Company granted B. Keith Clark, Senior Vice President and General Counsel, 30,000 stock options at an exercise price of \$13.82 per share. These options vest over three years and have a term of ten years.

The following assumptions were used to calculate the compensation expense related to granting 150,158 stock options in 2006:

	2006
Dividend yield:	2.6%
Risk-free interest rate:	4.3%
Expected market price volatility:	62.0%
Expected life of stock options:	4 years
Range of the fair value of options grants during the period:	\$11.16 \$14.16

8

For the three and nine months ended September 30, 2006, the Company recorded in selling, general and administrative expenses, compensation expense related to its stock-based compensation of \$0.2 million and \$0.5 million, respectively. This compensation expense related to existing unvested stock options outstanding prior to January 1, 2006 and granting of 150,158 stock options in 2006. For the three months and nine months ended September 30, 2006, the Company recorded a tax benefit related to stock option exercises of \$0.1 million and \$0.5 million, respectively. As of September 30, 2006, the Company expects to record compensation expense, in the future, as follows:

	Total gross unrecognized compensation expense	Total tax benefit associated with unrecognized compensation expense	Total net unrecognized compensation expense
For the three months ended December 31, 2006	\$ 0.2 million	\$ 0.1 million	\$ 0.1 million
For the twelve months ended December 31, 2007	0.6 million	0.2 million	0.4 million
For the twelve months ended December 31, 2008	0.3 million	0.1 million	0.2 million
For the twelve months ended December 31, 2009	0.1 million	0.0 million	0.1 million
	\$ 1.2 million	\$ 0.4 million	\$ 0.8 million

As of September 30, 2006, the Company had stock options outstanding, as follows:

		Weighted				
		average				
	Shares	exercise	Weighted- average	intrinsic value		
	(000s)	price	contractual term	(000s)		
Outstanding at December 31, 2005	1,237	\$ 6.09				
Granted	150	\$ 12.01				
Exercised	(203)	\$ 4.65		\$ 2,710		
Forfeited or expired	(29)	\$ 18.70				
Outstanding at September 30, 2006	1,155	\$ 6.79	5.3	\$ 12,619*		
Exercisable at September 30, 2006	889	\$ 5.54	5.3	\$ 10,829*		

^{*} The aggregate intrinsic value was calculated using the fair market value at September 30, 2006 minus the exercise price.

As of September 30, 2006, the Company had 314,687 stock options available for future grants. The following table summarizes information with respect to the Company s stock options outstanding and exercisable at September 30, 2006:

	()ptions outsta	nding	Options exercisable			
Exercise Price Range	Number	Weighted	Weighted average	Number	Weighted	Weighted average	
	of	average	remaining	of	average	remaining	
	shares	exercise	contractual	shares	exercise	contractual	

Edgar Filing: MANNATECH INC - Form 10-Q

		(000s)		price	life (in years)	(000s)	price	life (in years)
\$1.35	\$2.00	14	\$	1.82	0.7	14	\$ 1.82	0.7
\$2.50	\$2.69	44:	5 \$	2.65	4.1	445	\$ 2.65	4.1
\$3.49	\$4.00	1'	7 \$	3.50	5.6	17	\$ 3.50	5.6
\$7.45	\$8.20	440	5 \$	8.01	3.2	358	\$ 7.98	3.2
\$11.16	\$11.21	89	\$	11.20	9.7	8	\$ 11.21	9.7
\$12.23	\$12.44	7:	5 \$	12.37	9.0	25	\$ 12.37	9.0
\$13.82	\$14.16	30	5 \$	13.88	9.9		\$ 0.00	
\$17.05		2:	5 \$	17.05	8.8	14	\$ 17.05	8.8
\$20.64		8	\$	20.64	8.5	8	\$ 20.64	8.5
\$1.35	\$20.64	1,15	5 \$	6.79	5.3	889	\$ 5.54	5.3

Earnings Per Share

Basic Earnings Per Share (EPS) calculations are based on the calculated weighted-average number of the Company s common shares outstanding during the period. Diluted EPS calculations are based on calculated weighted-average number of common shares and dilutive common share equivalents outstanding during each period.

The following summarizes the calculated weighted-average amounts included in the Company s EPS and the effect on the weighted-average number of common shares and dilutive common share equivalents for the three months ended September 30, 2005 and 2006. At September 30, 2005, 61,757 of the Company s common stock options were excluded from the diluted EPS calculation, and as of September 30, 2006, 32,616 common stock options were excluded from the diluted EPS calculations as their exercise price was greater than the quarterly average fair market price of the Company s common stock and thus their effect on earnings was antidilutive. The amounts are rounded to the nearest thousands, except for per share amounts.

	Income	2005 Shares	Per shar	e Income	2006 Shares	Pe	r share
	(Numerator)	(Denominator)	amount	(Numerator)	(Denominator)	aı	nount
Basic EPS:							
Net income available to common shareholders	\$ 8,733	27,015	\$ 0.32	\$ 9,688	26,446	\$	0.37
Effect of dilutive securities: Stock options		616			492		(0.01)
Warrants		107			106		
Diluted EPS:							
Net income available to common shareholders plus assumed conversions	\$ 8,733	27,738	\$ 0.32	2 \$ 9,688	27,044	\$	0.36

The following summarizes the calculated weighted-average amounts included in the Company s EPS and the effect on the weighted-average number of common shares and dilutive common share equivalents for the nine months ended September 30, 2005 and 2006. At September 30, 2005, 61,757 of the Company s common stock options were excluded from the diluted EPS calculation, and as of September 30, 2006, 32,616 common stock options were excluded from the diluted EPS calculations as their exercise price was greater than the year-to-date average fair market price of the Company s common stock and thus their effect on earnings was antidilutive. The amounts are rounded to the nearest thousands, except for per share amounts.

	Income	2005 Shares	Per share		Per share		Per share		Per share		Per share		Income	2006 Shares	Pe	r share
	(Numerator)	(Denominator)	aı	nount	(Numerator)	(Denominator)	aı	nount								
Basic EPS:																
Net income available to common shareholders	\$ 19,212	27,065	\$	0.71	\$ 24,208	26,663	\$	0.91								
Effect of dilutive securities: Stock options		724		(0.02)		511		(0.02)								
Warrants		110				106										
Diluted EPS:																
Net income available to common shareholders plus assumed conversions	\$ 19,212	27,899	\$	0.69	\$ 24,208	27,280	\$	0.89								

NOTE 3 COMPREHENSIVE INCOME

Comprehensive income is the change in equity of a business enterprise during a period from transactions and other events and circumstances from nonowner sources and includes all changes in equity during a period except those resulting from investments by owners and distributions to owners. The Company s comprehensive income consists of foreign currency translation adjustments from its Japan, Republic of Korea, and Taiwan operations and unrealized gains/losses from its investments classified as available-for-sale. Comprehensive income is as follows:

	Three months ended		Nine mon	ths ended
	Septem	ber 30,	September 30,	
	2005	2006 (in the	2005 ousands)	2006
Net income	\$ 8,733	\$ 9,688	\$ 19,212	\$ 24,208
Foreign currency translation adjustments	(301)	(794)	(988)	(530)
Unrealized gain from investments classified as available-for-sale, net of related tax effect ⁽¹⁾	2		5	15
Comprehensive income	\$ 8,434	\$ 8,894	\$ 18,229	\$ 23,693

⁽¹⁾ The net tax effect for unrealized gains from investments available-for-sale for the three months ended September 30, 2005 and 2006, was \$3 and \$1, respectively. The net tax effect for unrealized gains from investments available-for-sale for the nine months ended September 30, 2005 and 2006, was \$5 and \$9, respectively.

NOTE 4 INVESTMENTS

The Company classifies its investments as available-for-sale. At December 31, 2005 and September 30, 2006, the Company s investments consisted of the following:

	Amortized	December 3 Gross	Fair	
	cost	unrealized		value
Federal Home Loan Bank bond	\$ 2,000	\$	(26)	\$ 1,974
State or federal agency backed obligations	15,375			15,375
Total investments	\$ 17,375	\$	(26)	\$ 17,349

	Amortized	Fair	
	cost	Gross unrealized (gain) loss (in thousands)	value
Corporate money-market fund	\$ 12,925		\$ 12,925
State or federal agency backed obligations	12,450		12,450
Total investments	\$ 25,375		\$ 25,375

The fair values of the Company s investments by contractual maturity at December 31, 2005 and September 30, 2006, were as follows:

Edgar Filing: MANNATECH INC - Form 10-Q

		September			
	December 31, 2005		2006		
	(in th	(in thousands)			
Due in one year or less	\$ 1,974	\$			
Due between one and five years					
Due after ten years	15,375		25,375		
	\$ 17,349	\$	25,375		

NOTE 5 INVENTORIES

Inventories consist of raw materials, work in progress, finished goods, and sales aids that are stated at the lower of cost (using standard costs that approximate average costs) or market. Work in progress includes raw materials shipped to a third-party manufacturer to process further for use, by the Company, into certain finished goods. The Company provides an allowance for any slow-moving or obsolete inventories. Inventories at December 31, 2005 and September 30, 2006, consisted of the following:

	December 31,	Sept	ember 30,	
	2005		2006	
	(in thousands)			
Raw materials	\$ 5,759	\$	5,541	
Work in progress			106	
Finished goods, less inventory reserves for obsolescence of \$387 in 2005 and \$379 in 2006	14,052		14,498	
	\$ 19 811	\$	20 145	

NOTE 6 TRANSACTIONS WITH AFFILIATES AND RELATED PARTIES

<u>MannaRelief.</u> The Company s Chairman and Chief Executive Officer, Samuel L. Caster, founded MannaRelief in 1999 and has served as its Chairman since inception. Defined under the Internal Revenue Code, MannaRelief is a 501(c)(3) charitable organization that provides services for children. Donald Herndon, the Company s Vice President of Field Services, also serves on MannaRelief s Board. Mr. Herndon is the brother-in-law of Mr. Caster and the brother-in-law of Terry L. Persinger, who is the Company s President and Chief Operating Officer and a member of the Company s Board of Directors.

Historically, the Company has made cash donations to MannaRelief, sold certain of its products to MannaRelief at cost plus shipping and handling charges, and shipped products purchased by MannaRelief to its chosen recipients. In addition, certain Company employees and consultants periodically volunteer to work on various fund raising projects and events for MannaRelief at no cost to MannaRelief. The Company has made cash donations and sold products to MannaRelief, at cost plus shipping and handling, as follows:

	Three mor	nths ended	Nine months ended		
	Septem	ıber 30,	September 30,		
	2005	2005 2006		2006	
Sold Products	\$ 0.3 million	\$ 0.4 million	\$ 1.0 million	\$ 1.0 million	
Cash Donations	\$ 0.1 million	\$ 0.2 million	\$ 0.3 million	\$ 0.5 million	

Clinical Study. In June 2004, the Company signed a cancelable three-year research agreement with St. George s Hospital & Medical School, in London, England, to fund research costs related to a clinical trial involving one of the Company s products. The principal investigator in the clinical trials, Dr. John Axford, is employed by St. George s Hospital & Medical School and is also a member of the Company s Board of Directors and Chairman of its Science Committee. Pursuant to this 2004 research agreement, the Company agreed to fund approximately \$0.7 million over three years for this study. This is the second clinical study funded by the Company for St. George s Hospital & Medical School. For the three and nine months ended September 30, 2005, the Company paid \$0.2 and \$0.4 million, respectively, toward this clinical study. For both the three and nine months ended September 30, 2006, the Company paid \$0.1 million toward this study.

<u>Fredrick Media, LLC.</u> In November 2005, the Company entered into a consulting services agreement with Fredrick Media, LLC, which is owned by Mr. Landen Fredrick, son of Mr. J. Stanley Fredrick, who serves as the Lead Director on the Company s Board of Directors. Pursuant to the consulting agreement, the Company agreed to pay approximately \$0.2 million to Fredrick Media, LLC for various marketing consulting services, including consulting related to the development of the Company s website. Through May 2006, the Company paid Fredrick Media, LLC approximately \$0.1 million related to this consulting agreement. In May 2006, the Company terminated the consulting agreement with Fredrick Media, LLC and hired its founder, Mr. Landen Fredrick, as its Senior Director of Associate Initiatives.

12

Receivables due from affiliates. On February 17, 1999, the Company signed five separate notes receivable agreements with five shareholders who were also affiliates of the Company. The notes with installments were due annually through February 17, 2004. On June 4, 2001, the Company agreed to modify the terms of the note receivable with Mr. Charles Fioretti as part of his separation and release as Chairman and Chief Executive Officer of the Company. As modified, Mr. Fioretti s remaining principal balance of \$127,000 would continue to accrue interest and would mature on the earlier of February 17, 2011, or 13 days after the date in which Mr. Fioretti no longer continued to own at least 100,000 shares of the Company s common stock. During 2005, Mr. Fioretti s ownership of the Company s common stock fell below 100,000 shares, and as a result, the note became due to the Company and was classified as a current asset. The Company believes the note is collectible and is negotiating with Mr. Fioretti to pay the remaining principal and interest related to his note, which as of September 30, 2006 was approximately \$160.000.

Agreement with a Director. In November 2003, the Company entered into a Lock-Up Agreement whereby the Company pays Mr. J. Stanley Fredrick, the Company s Lead Director on its Board of Directors and a major shareholder, \$185,000 per year for his agreement not to sell his shares unless approved by the Board of Directors. As of September 30, 2006, Mr. Fredrick continues to hold 3,150,000 shares, or 11.9%, of the Company s common stock.

In November 2003, the Company also agreed to pay Mr. Fredrick \$0.1 million annually to act as its Lead Director for its Board of Directors. In January 2006, the Company began paying Mr. Fredrick director meeting fees associated with attending its Board of Directors and Committee meetings.

Certain transactions with Ray Robbins. Marlin Ray Robbins is a member of the Company s Board of Directors and major shareholder. Mr. Robbins also holds multiple positions in the Company s associate global downline network marketing system, four of which related to the cancellation of an agreement between the Company and Mr. Robbins in June 1999. The Company pays commissions and incentives to its independent associates for product sales and downline growth. During 2005 and 2006, the Company paid commissions to Mr. Robbins totaling \$2.3 million and \$2.5 million, respectively. In addition, several of Mr. Robbins children are also independent associates and were paid associate commissions of approximately \$0.3 million for both 2005 and 2006, respectively. All commissions paid to Mr. Robbins and his immediate family members were paid in accordance with the Company s global associate career and compensation plan.

NOTE 7 COMMITMENTS AND CONTINGENCIES

Royalty and Consulting Agreements

In August 2003, the Company entered into a Long-Term Post-Employment Royalty Agreement with Dr. Bill McAnalley, who served as the Company s Chief Science Officer, pursuant to which the Company was required to pay Dr. McAnalley or his heirs—royalties for 10 years beginning September 2005 through August 2015. Under the terms of this agreement, the Company is required to make quarterly payments based on certain applicable annual global finished product sales, by the Company, in excess of \$105.4 million. Beginning in August 2003, the Company was required to measure and accrue the present value of the estimated future royalty payments related to the long-term post-employment royalty benefit associated with this agreement and recognize it over the life of Dr. McAnalley s employment agreement, which ended August 2005. During 2005, the Company paid \$0.1 million related to this agreement and accrued a total of \$3.9 million. During 2006, the Company paid \$0.3 million and accrued a total of \$3.5 million related to this agreement.

13

On August 7, 2005, the two year employment agreement with Dr. McAnalley expired. As a result, the Company entered into a Release Agreement and a one-year Consulting Agreement in which the Company was required to pay Dr. McAnalley a total of \$0.9 million. In August 2006, the Company renewed Dr. McAnalley s consulting agreement for one year and agreed to pay him a total of \$0.5 million. As of September 30, 2006, the Company paid \$0.9 million to Dr. McAnalley related to his consulting agreements.

On June 1, 2006, the Company entered into a one-year Consulting and Separation Agreement with Ms. Bettina Simon, who served as the Company s Senior Vice President and Chief Legal Officer. Under the terms of this Agreement, the Company began paying Ms. Simon a total of \$0.1 million for litigation consulting support.

Letters of Credit

The Company offers an annual travel incentive for its independent associates who qualify for its annual travel incentive. The United States travel incentive for both 2006 and 2007 is a cruise on a Royal Caribbean International® cruise ship. Royal Caribbean requires its customers to provide a letter of credit as a security deposit against damages to the ship. At September 30, 2006, the Company restricted cash related to two letters of credit from its bank totaling \$2.0 million as collateral for its travel incentive cruises.

Employment Agreements

In August 2006, the Company signed a two year employment agreement with Mr. B. Keith Clark to serve as its Senior Vice President and General Counsel. Pursuant to the terms of the employment agreement, the Company agreed to pay Mr. Clark an annual salary of \$250,000, furnish him a leased vehicle, and allow him to participate in all employee benefits available to its other executives. In addition, under the terms of the agreement, if Mr. Clark resigns for good reason, or if the Company terminates his employment without cause or due to disability, the Company is obligated to pay Mr. Clark any unpaid but earned salary and bonus and any other benefits vested through the date of termination and the greater of twelve month salary or the salary remaining for the then current term of employment. On August 28, 2006, the Company s Board of Directors agreed to grant Mr. Clark 30,000 stock options with an exercise price of \$13.82. The stock options will vest over 3 years and, if not forfeited or exercised, will expire in ten years.

NOTE 8 CAPITAL LEASE OBLIGATION

In March 2006, the Company leased its fire and security system through a five year capital lease totaling \$0.4 million. The lease accrues interest at 6.2% and expires in March 2011.

NOTE 9 LITIGATION

The Company has been sued in three securities class action lawsuits in the United States District Court for the District of New Mexico, which remain pending.

First, on August 1, 2005, Mr. Jonathan Crowell filed a putative class action lawsuit against the Company and Mr. Samuel L. Caster, its Chief Executive Officer, on behalf of himself and all others who purchased or otherwise acquired the Company s common stock between August 10, 2004 and May 9, 2005, inclusive, and who were damaged thereby.

Second, on August 30, 2005, Mr. Richard McMurry filed a class action lawsuit against the Company, Mr. Caster, Mr. Terry L. Persinger, its President and Chief Operating Officer, and Mr. Stephen D. Fenstermacher, its Chief Financial Officer.

Third, on September 5, 2005, Mr. Michael Bruce Zeller filed a class action lawsuit against the Company, Mr. Caster, Mr. Persinger, and Mr. Fenstermacher.

The allegations in these class action lawsuits are substantially identical. The complaints allege the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 thereunder, claiming that defendants artificially inflated the value of the Company s common stock by knowingly allowing independent contractors to recklessly misrepresent the efficacy of its products during the purported class period.

14

On December 12, 2005, the Court granted a motion to consolidate the three putative class action lawsuits into one civil action styled In re Mannatech, Incorporated Securities Litigation. Also, on January 4, 2006, the Court entered an order appointing The Mannatech Group, consisting of Mr. Austin Chang, Ms. Naomi S. Miller, Mr. John C. Ogden, and the Plumbers and Pipefitters Local 51 Pension Fund, as lead plaintiffs and appointing the law firms Lerach Coughlin Stoia Geller Rudman & Robbins LLP, as lead counsel, and Freedman Boyd Daniels Hollander & Goldberg, P.A., as liaison counsel, for the putative class. On March 3, 2006, the lead plaintiffs filed an amended consolidated class action complaint.

The Company s motion to transfer venue to the United States District Court, Dallas Division, in the consolidated class action lawsuits remains pending before the Court. Both sides have submitted briefings on the issue of transfer and the Company filed a Notice of Completion of Briefing with the Court on June 28, 2006. The Company anticipates the Court will rule on this motion in the coming months.

The Company has also been sued in three shareholder derivative lawsuits, which remain pending.

First, on October 18, 2005, a shareholder derivative lawsuit was filed by Norma Middleton, Derivatively and on Behalf of Nominal Defendant, Mannatech, Incorporated against Samuel L. Caster, Terry L. Persinger, Donald A. Buchholz, J. Stanley Fredrick, Gerald E. Gilbert, Alan D. Kennedy, Marlin Ray Robbins, and Patricia A. Wier, in the United States District Court for the Northern District of Texas, Dallas Division.

Second, on January 11, 2006, a shareholder derivative action was filed by Kelly Schrimpf, Derivatively and on Behalf of Nominal Defendant Mannatech, Incorporated against Samuel L. Caster, Terry L. Persinger, Steven W. Lemme, and Stephen D. Fenstermacher in the 162nd District Court of Dallas County, Texas.

Third, on January 13, 2006, a shareholder derivative action was filed by Frances Nystrom, Derivatively and on Behalf of Nominal Defendant Mannatech, Incorporated against Samuel L. Caster, Terry L. Persinger, Stephen D. Fenstermacher, John Stuart Axford, J. Stanley Fredrick, Gerald E. Gilbert, Alan D. Kennedy, Marlin Ray Robbins, Patricia A. Wier, and Donald A. Buchholz in the United States District Court for the Northern District of Texas, Dallas Division.

Each of these shareholder derivative lawsuits makes allegations similar to the allegations of the shareholder class action litigation described above.

The Company s independent directors appointed a Special Litigation Committee to review these matters and determine the proper corporate response. This review was completed on August 26, 2006 and the Special Litigation Committee issued its report, determining that it is in the best interests of the Company to dismiss the derivative lawsuits. Statements by the Company to this effect were filed with the courts in the respective derivative cases on September 13, 2006.

The Schrimpf state court lawsuit is presently stayed pending the final disposition of the Middleton federal lawsuit, the first-filed derivative action. The Company s motions to stay in the Middleton and Nystrom federal court lawsuits, pursuant to Texas Business Corporation Act art. 5.14, have been denied by the Court. The motion to consolidate the Middleton and Nystrom lawsuits filed by the Company remains pending, as does a separate motion to consolidate filed by Middleton on August 17, 2006. Competing motions to appoint lead plaintiff and lead counsel have also been filed by both Middleton and Nystrom. These motions were filed August 17, 2006, and September 6, 2006, respectively, and remain pending.

The Company has reached an agreement with each of the derivative plaintiffs counsel, as well as with counsel for the lead plaintiffs in the consolidated securities class action, to explore an early mediation. Therefore the parties in the derivative suits have filed agreed motions to extend for 90 days the date by which the defendants must file their answer, motion to dismiss, or otherwise file a responsive pleading. These motions are pending before the court.

Plaintiffs in the consolidated putative class actions and in the shareholder derivative actions seek an unspecified amount of compensatory damages, interest and costs, including legal and expert fees.

15

In response to these actions, the Company continues to work with its experienced securities litigation counsel to vigorously defend the Company and its officers and directors. It should be noted that a court must certify a class before a case can proceed as a class action lawsuit and that the determination has not been made in the consolidated securities cases. The Company believes these types of repetitive lawsuits (seeking class action status) are common in today s litigious society and many reputable companies have successfully defended themselves against such litigation. It is not possible at this time to predict whether the Company will incur any liability, or to estimate the damages or the range of damages, if any, that the Company might incur in connection with any of these above mentioned securities and derivative lawsuits.

On March 16, 2006, the Company filed a patent infringement lawsuit against Glycobiotics International, Inc. for alleged infringement of the Company's utility U.S. Patent No. 6,929,807 (Compositions of Plant Carbohydrates as Dietary Supplements) in the United States District Court of the Northern District of Texas. The Company sued Glycobiotics to cease the manufacture, sale, and use of its glyconutritional product marketed under the brand name Glycomannan and for alleged unfair competition due to false and misleading statements. In April 2006, Glycobiotics filed its response and asserted various affirmative defenses. The Company intends to vigorously prosecute the case. The case is currently in the initial phases of discovery and the Company expects a trial date in 2007.

On May 5, 2006, the Company also filed a patent infringement lawsuit against Techmedica Health Inc. for alleged infringement of the Company's utility U.S. Patent No. 6,929,807 (Compositions of Plant Carbohydrates as Dietary Supplements) in the United States District Court of the Northern District of Texas, Dallas Division. The Company sued Techmedica Health to cease the manufacture, sale, and use of its glyconutritional product marketed under the brand name Nutratose and for alleged unfair competition due to false and misleading statements. In June 2006, the Company filed an objection to the change in venue filed by Techmedica Health Inc. The court agreed with the Company's position and denied Techmedica's motion to transfer on August 3, 2006. The Company intends to vigorously prosecute the case. The case is currently in the discovery phase and the Company expects a trial date in early 2008.

The Company also has several pending claims incurred in the normal course of business. In the opinion of the Company s management, such claims can be resolved without any material affect on its consolidated financial position, results of operations, or cash flows.

The Company maintains certain liability insurance in amounts it believes is adequate. However, certain costs of defending lawsuits, such as those below the insurance deductible amount, are not covered by or only partially covered by its insurance policies, and its insurance carriers could refuse to cover certain of these claims in whole or in part.

NOTE 10 RECENT ACCOUNTING PRONOUNCEMENTS

FAS 157. In September 2006, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 157, Fair Value Measurements , (FAS 157). The provisions of FAS 157 define fair value, establish a framework for measuring fair value in generally accepted accounting principles, and expand disclosures about fair value measurements. The provisions of FAS 157 are effective for fiscal years beginning after November 15, 2006. The Company does not believe the adoption of FAS 157 will have a significant effect on its consolidated financial position, results of operations, or cash flows.

FAS 158. In September 2006, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 158, Employer's Accounting for Defined Benefit Pension and Other Postretirement Plans, an amendment of FASB Statements No. 87, 88, 106, and 132R , (FAS 158). Under the provisions of FAS 158, a company is required to recognize in its statement of financial condition the funded status of its defined benefit postretirement plans, measured as the difference between the fair value of the plan assets and the benefit obligation. FAS 158 also requires a company to recognize changes in the funded status of a defined benefit postretirement plan within accumulated other comprehensive income, net of tax, to the extent such changes are not recognized in earnings as components of periodic net benefit cost. FAS 158 is effective as of the end of the fiscal year ending after December 15, 2006. The Company maintains a Defined Benefit Plan for its Japan subsidiary and is currently assessing the impact of the adoption of this statement to its consolidated financial position, results of operations, or cash flows.

16

FIN 48. In July 2006, the Financial Accounting Standards Board issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109, (FIN 48). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an entity s financial statements in accordance with FAS 109 and prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Additionally, FIN 48 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006, with early adoption permitted. The Company is currently evaluating whether the adoption of FIN 48 will have a material effect on its consolidated financial position, results of operations, or cash flows.

SAB 108. In September 2006, the United States Securities and Exchange Commission issued Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements When Quantifying Misstatements in Current Year Financial Statements , (SAB 108). SAB 108 provides interpretive guidance on how the effects of the carryover or reversal of prior year misstatements should be considered in quantifying a current year misstatement. SAB 108 is effective for fiscal years ending after November 15, 2006. The Company does not believe the adoption of SAB 108 will have a material impact on its consolidated financial position, results of operations, or cash flows.

NOTE 11 SEGMENT INFORMATION

The Company conducts its business within one industry segment. No single independent associate has ever accounted for more than 10% of its total sales.

The Company aggregates all of its operating units because it operates as a single reportable segment as a seller of nutritional supplements through its network-marketing distribution channels operating in ten different countries. In each country, the Company markets its products and pays commissions and incentives in similar market environments. The Company s management reviews its financial information by country and focuses its internal reporting and analysis of revenues by packs and product sales. The Company sells its products through its independent associates and distributes its products through similar distribution channels in each country. Each of the Company s operations sells similar packs and products and possesses similar economic characteristics such as similar selling prices and gross margins.

The Company has six active subsidiaries that operate in six physical locations and sell products in ten different countries around the world. The six physical locations include the United States, Australia, the United Kingdom, Japan, the Republic of Korea, and Taiwan. Each of the Company s physical locations service different geographical areas. The United States parent processes orders for Canada; however, products and packs sold in Canada are shipped through a third party distribution facility located in Canada. The Company s Australia location processes orders for both Australia and New Zealand, and the orders are shipped for Australia and New Zealand through a third party distribution facility located in Australia. The Company s United Kingdom location processes and ships orders for the United Kingdom, Denmark, and Germany.

All of the Company s six active subsidiaries are fully operating subsidiaries, except for Australia and the United Kingdom. The Company s Australian and United Kingdom subsidiaries operate as limited-risk service providers and are responsible for providing management, marketing and administrative services, processing and shipping orders, and overseeing the payment of cost of sales and commissions for processed orders on behalf of its parent operating in the United States. For these services, the limited-risk service providers are paid a management fee from the United States parent, which is eliminated in the Company s consolidated financial statements. In addition to the processing and shipping of orders in the United States and Canada, the United States parent owns all of the sales and inventories and accrues all commissions and costs related to activities in New Zealand, Australia, the United Kingdom, Denmark, and Germany.

17

By country of operation, consolidated net sales primarily shipped to customers in these locations, along with pack and product information for the three and nine months ended September 30, 2005 and 2006, respectively, are as follows:

					I	Nine montl	hs ended	
	Three months ended September 30,			September 30,				
	200	2005 2006			2005		200	6
		(in milli			(in millions)			
United States	\$ 66.5	66.3%	\$ 65.7	66.0%	\$ 192.3	66.8%	\$ 202.8	66.9%
Canada	7.0	7.0%	6.7	6.7%	20.9	7.3%	21.6	7.1%
Australia	9.3	9.3%	7.5	7.5%	26.3	9.1%	22.8	7.5%
United Kingdom	2.1	2.1%	1.8	1.9%	6.9	2.4%	5.7	1.9%
Japan	9.1	9.1%	10.0	10.0%	25.9	9.0%	30.1	9.9%
New Zealand	3.7	3.7%	2.1	2.1%	11.3	3.9%	6.8	2.2%
Republic of Korea	1.5	1.5%	3.3	3.3%	2.9	1.0%	7.2	2.4%
Taiwan*	0.9	0.9%	0.8	0.8%	1.3	0.5%	2.7	0.9%
Denmark**	0.1	0.1%	1.0	1.0%	0.1	0.0%	2.4	0.8%
Germany***		%	0.7	0.7%		%	1.2	0.4%
•								
Totals	\$ 100.2	100%	\$ 99.6	100%	\$ 287.9	100%	\$ 303.3	100%

^{*} Taiwan began its operations in June 2005.

^{***} United Kingdom began shipping products to Germany in March 2006.

		September 30, 2005 2006 (in millions)			Nine months ended September 30,	
					2005 (in mi	2006
Consolidated product sales	\$,		_	\$ 208.2	
Consolidated pack sales		22.5		17.9	69.0	61.9
Consolidated other, including freight		5.2		6.1	10.7	14.0
Consolidated total net sales	\$	100.2	\$	99.6	\$ 287.9	\$ 303.3

Long-lived assets, which include property, plant and equipment and construction in progress for the Company and its subsidiaries, are as follows:

	December 3	31, Sept	ember 30,	
Country	2005	(in millions)	2006	
Australia	\$ 0.2	\$	0.2	
Japan	0.3		0.3	
Republic of Korea	0.6		0.5	
Taiwan	0.3		0.2	
United Kingdom	0.5		0.5	
United States	17.2		34.4	
Total long-lived assets	\$ 19.1	\$	36.1	

^{**} United Kingdom began shipping products to Denmark in August 2005.

18

Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion is intended to assist in the understanding of our consolidated financial position and results of operations for the three and nine months ended September 30, 2006 as compared to the same periods in 2005. Unless stated otherwise, all financial information presented below, throughout this report, and in the consolidated financial statements and related notes includes Mannatech and all of our subsidiaries on a consolidated basis.

Company Overview

We began operations in November 1993 to develop innovative, high-quality, proprietary nutritional supplements, skin-care and topical products, and weight-management products that are now sold in the United States, Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark and Germany. We operate as a single segment and primarily sell our products through approximately 536,000 independent associates and members who have purchased our products and/or packs within the last 12 months. We refer to these independent associates and members as *current independent associates and members*. Our quarterly summary of net sales, net income, diluted earnings per share, and changes in products, are as follows:

Net sales decreased by \$0.6 million, or 0.7%, for the three months ended September 30, 2006 and increased by \$15.4 million, or 5.3%, for the nine months ended September 30, 2006, as compared to the same periods in 2005.

The introduction of our optimal skin care system in Japan in May 2006 increased our net sales by \$1.0 million and \$2.3 million, for the three and nine months ended September 30, 2006, as compared to the same period in 2005.

Net income increased by \$1.0 million, or 10.9%, for the three months ended September 30, 2006 and increased by \$5.0 million, or 26.0%, for the nine months ended September 30, 2006, as compared to the same periods in 2005.

Diluted earnings per share increased \$0.04 per share, or 12.5%, for the three months ended September 30, 2006 and increased \$0.20 per share, or 29.0%, for the nine months ended September 30, 2006, as compared to the same periods in 2005.

We discontinued Life Enhancement Packs in August 2006, which was a combination of three of our products bundled into individual packets. We plan to introduce a similar individually bundled packet with our newer and improved products. In addition, in September 2006, we decided to continue selling our Ambrotose® capsules because we believe this product is still in demand

We launched our skin care products in the Republic of Korea in October 2006 and plan to launch our optimal skin care system in Australia, the United Kingdom, and the United States within the next six months.

During the fourth quarter of 2006, we plan to introduce into the United States, Canada, Australia, and New Zealand, our new supplement PhytoMatrix that contains a unique blend of plant-based minerals, natural vitamin complexes and standardized phytochemicals.

We were disappointed with the decrease in our consolidated net sales for the quarter, but believe the measures we began implementing will help reverse the decrease in net sales over time. Together with our Management team focused on operations, we believe these measures will allow us to achieve positive sales growth in the future. However, we can give no assurances that these measures will produce the intended positive sales growth.

19

Critical Accounting Policies and Estimates

In response to SEC Release No. 33-8040, Cautionary Advice Regarding Disclosure About Critical Accounting Policies, we review our policies related to the portrayal of our consolidated financial position and consolidated results of operations that require the application of significant judgment by management. We also analyze the need for certain estimates, including the need for such items as inventory reserves, capitalization of software development costs, tax valuation allowances, revenue recognition and deferred revenues, accounting for stock based compensation, and contingencies and litigation. Our estimates are based on historical experience, industry standards, and various other assumptions that we believe are applicable and reasonable under the circumstances. We caution readers that actual results could differ from estimates under different assumptions or conditions, and if circumstances change relating to the various assumptions or conditions used in our estimates, we could experience an adverse effect on our consolidated financial position, consolidated results of operations, and consolidated cash flows. We have identified the following applicable critical accounting policies and estimates as of September 30, 2006:

Inventory Reserves

We review our inventory carrying value and compare it to the estimated fair market value. Any inventory value in excess of estimated fair market value is written down. In addition, we review our inventory for obsolescence and any inventory identified as obsolete is reserved or written off. Our determination of obsolescence is based on assumptions about the demand for our products, product expiration dates, estimated future sales, and future plans. If actual sales are less favorable than those originally projected by us, additional inventory reserves or write-downs may be required. At September 30, 2006, our net inventories were valued at \$20.1 million, which included an inventory reserve for slow-moving and obsolete inventories of approximately \$0.4 million.

Capitalization of Software Development Costs

We capitalize costs associated with internally-developed software projects and amortize costs associated with these projects over their useful lives, which is usually five years. If accounting standards change or if the capitalized software becomes obsolete, we may be required to write-off our unamortized capitalized software or accelerate the amortization period.

During 2004, we began the development and/or configuration of several large-scaled information technology projects that are intended to increase functionality of our operations and expand our reporting capabilities. One of these projects was the configuration of our internally-developed global re-architecture software project, also called our Oracle/JDE Globalview fully-integrated software project. As of September 30, 2006, we had approximately \$2.7 million of unamortized capitalized software development costs included in property and equipment and \$21 million included in construction in progress, which we plan to put in service in April 2007 and amortize ratably over its expected useful life of 5 years.

Tax Valuation Allowances

We evaluate the probability of realizing the future benefits of our deferred tax assets and record a valuation allowance when we believe that a portion or all of our deferred tax assets may not be realized. If we are unable to realize the expected future benefits of our deferred tax assets, we are required to provide a valuation allowance. As of September 30, 2006, our total gross deferred tax assets were \$4.2 million, and we recorded a valuation allowance of \$0.7 million related to certain deferred tax assets for our operations in Taiwan and the Republic of Korea as they do not meet the *more likely than not* criteria, as defined by the recognition and measurement provisions of Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes .

20

Revenue Recognition and Deferred Revenues

We defer all revenues until our customers receive their shipments. We also defer a portion of our revenues from the sales of certain starter and renewal packs that contain a one-year magazine subscription and defer a portion of revenue from each pack in which the total price of the pack exceeds the total wholesale value of all individual components included in such packs. We amortize the deferred revenues associated with our one-year magazine subscriptions and any pack sales that exceed the total wholesale value of the individual components included in such packs over twelve months. Although we have no immediate plans to significantly change the contents of our packs or our shipping methods, any such change in the future could result in additional revenue deferrals or cause us to recognize deferred revenue over a longer period of time. For example, if we were to decrease the number of items included in our packs but not change the sales price of our packs, we would have to defer additional revenue and recognize the additional deferred revenue over twelve months.

Accounting for Stock-Based Compensation

Under FAS 123R, we are required to measure and recognize compensation expense related to any unvested stock options outstanding on January 1, 2006, granted to our employees and board members and recognize compensation expense for any new stock options granted after December 31, 2005. For the nine months ended September 30, 2006, the measurement is based on various assumptions, which are as follows:

average dividend yield of 2.6%;

expected average risk-free interest rate of 4.3 %;

expected market price volatility of 62.0%; and

expected average life of stock options of 4 years.

Based upon the above assumptions, we record the calculated compensation expense in our consolidated statements of operations over the stock options vesting periods, which are generally two or three years. As of September 30, 2006, we anticipate recognizing \$1.2 million in compensation expense through 2009 related to unvested stock options outstanding. In addition, we have 314,687 stock options available to grant in the future.

Contingencies and Litigation

Each quarter, we evaluate the need to accrue for legal claims or assessments. We base our accrual evaluation on our estimated amount of damages and the probability of losing any threatened legal claim. If circumstances change or we experience an unanticipated adverse outcome of any legal action, we would be required to increase our estimated amount accrued related to any potential legal action.

21

Results of Operations

The tables below summarize our consolidated operating results in dollars (rounded to the nearest thousand) and as a percentage of net sales for the three and nine months ended September 30, 2005 and 2006.

Consolidated Operating Results for the three months ended September 30, 2005 and 2006

					Chan	ge from	
	200	5	200	06	2005 to 2006		
	Total	% of	Total	% of	Dollar	Percentage	
	dollars	net sales	dollars	net sales	change	change	
Net sales	\$ 100,216	100%	\$ 99,558	100%	\$ (658)	(0.7)%	
Cost of sales	14,478	14.4%	13,497	13.5%	(981)	(6.8)%	
Commissions and incentives	44,403	44.3%	43,977	44.2%	(426)	(1.0)%	
	58,881	58.7%	57,474	57.7%	(1,407)	(2.4)%	
Gross profit	41,335	41.3%	42,084	42.3%	749	1.8%	
Operating expenses:							
Selling and administrative expenses	16,136	16.1%	16,562	16.7%	426	2.6%	
Other operating costs	12,415	12.4%	14,051	14.1%	1,636	13.2%	
Total operating expenses	28,551	28.5%	30,613	30.8%	2,062	7.2%	
	·		·		,		
Income from operations	12,784	12.8%	11,471	11.5%	(1,313)	(10.3)%	
Interest income	469	0.5%	599	0.6%	130	27.7%	
Other income (expense), net	(288)	(0.3)%	670	0.7%	958	332.6%	
Income before income taxes	12,965	13.0%	12,740	12.8%	(225)	(1.7)%	
Provision for income taxes	(4,232)	(4.3)%	(3,052)	(3.1)%	1,180	(27.9)%	
Net income	\$ 8,733	8.7%	\$ 9,688	9.7%	\$ 955	10.9%	

Consolidated Operating Results for the nine months ended September 30, 2005 and 2006

					Chan	ge from	
	200	2005		6	2005	to 2006	
	Total	% of	of Total	% of	Dollar	Percentage	
	dollars	net sales	dollars	net sales	change	change	
Net sales	\$ 287,960	100%	\$ 303,300	100%	\$ 15,340	5.3%	
Cost of sales	43,186	15.0%	42,777	14.1%	(409)	(0.9)%	
Commissions and incentives	129,326	44.9%	135,349	44.6%	6,023	4.7%	
	172,512	59.9%	178,126	58.7%	5,614	3.3%	
Gross profit	115,448	40.1%	125,174	41.3%	9,726	8.4%	

Operating expenses:

Edgar Filing: MANNATECH INC - Form 10-Q

Selling and administrative expenses	48,595	16.9%	52,569	17.4%	3,974	8.2%
Other operating costs	36,587	12.7%	39,724	13.1%	3,137	8.6%
Total operating expenses	85,182	29.6%	92,293	30.5%	7,111	8.3%
Income from operations	30,266	10.5%	32,881	10.8%	2,615	8.6%
Interest income	1,254	0.4%	1,763	0.6%	509	40.6%
Other income (expense), net	(1,188)	(0.4)%	805	0.3%	1,993	167.8%
Income before income taxes	30,332	10.5%	35,449	11.7%	5,117	16.9%
Provision for income taxes	(11,120)	(3.8)%	(11,241)	(3.7)%	(121)	1.1%
Net income	\$ 19,212	6.7%	\$ 24,208	8.0%	\$ 4,996	26.0%

Three and nine months ended September 30, 2006 compared with the same periods in 2005

Net Sales

We sell our nutritional supplements through network-marketing distribution channels operating in 10 different countries. We review and analyze our net sales by geographical location and further analyze our net sales by packs and products. Each of our subsidiaries sells the same type of products and possesses similar economic characteristics, such as similar selling prices and gross margins. Consolidated net sales primarily shipped to customers in these locations, in dollars and as a percentage of consolidated net sales, for the three and nine months ended September 30, are as follows:

Net Sales in Dollars and as a Percentage of Consolidated Net Sales

					ľ	Nine montl	hs ended			
		Three months ended September 30,				September 30,				
	200	in milli	200 ons)	06	200:	o (in mill	200 ions)	b		
United States	\$ 66.5	66.3%	\$ 65.7	66.0%	\$ 192.3	66.8%	\$ 202.8	66.9%		
Canada	7.0	7.0%	6.7	6.7%	20.9	7.3%	21.6	7.1%		
Australia	9.3	9.3%	7.5	7.5%	26.3	9.1%	22.8	7.5%		
United Kingdom	2.1	2.1%	1.8	1.9%	6.9	2.4%	5.7	1.9%		
Japan	9.1	9.1%	10.0	10.0%	25.9	9.0%	30.1	9.9%		
New Zealand	3.7	3.7%	2.1	2.1%	11.3	3.9%	6.8	2.2%		
Republic of Korea	1.5	1.5%	3.3	3.3%	2.9	1.0%	7.2	2.4%		
Taiwan*	0.9	0.9%	0.8	0.8%	1.3	0.5%	2.7	0.9%		
Denmark**	0.1	0.1%	1.0	1.0%	0.1	0.0%	2.4	0.8%		
Germany***		%	0.7	0.7%		%	1.2	0.4%		
Totals	\$ 100.2	100%	\$ 99.6	100%	\$ 287.9	100%	\$ 303.3	100%		

^{*} Taiwan began operations in June 2005.

Overall, our consolidated net sales for the nine months ended September 30, 2006 increased by \$15.4 million, or 5.3%, as compared to the same period in 2005. However, for the quarter ended September 30, 2006, our consolidated net sales decreased by \$0.6 million, or 0.7%, as compared to the same period in 2005. The decrease was due to lower net sales in North America, Australia, New Zealand, and the United Kingdom. We believe the decrease in net sales in the United States and Canada may have been caused by consumer distractions created by the class action suit, filed in May 2005, and continued consumer questions concerning the reformulation of Advanced Ambrotose . We believe the change in the United Kingdom net sales was the result of heightened activities in the new markets of Denmark and Germany.

We believe the decrease in net sales in Australia and New Zealand is the result of the negative reaction to the original formulation of Advanced Ambrotose . We introduced our original formulation of Advanced Ambrotose in the United States in March 2005 and in other countries in the second half of 2005. Initial reaction by some consumers to the original formula of Advanced Ambrotose was unfavorable. As a result, we introduced a reformulated Advanced Ambrotose in mid 2006. The reformulated Advanced Ambrotose contains a compound that is created using the latest technology, which allows for a more potent concentration of the full size range of mannose-containing polysaccharides occurring naturally in aloe into a stable powdered form. This process allows the compound to possess the most potent and profound immunostimulatory properties because it does not strip the compound of its natural mineral counterparts by organic solvent precipitation, and most importantly, allows the compound to retain a high proportion of molecular weight polysaccharides, which are believed to be responsible for the effective immune stimulating properties of aloe. This enhanced immune stimulating capability has been demonstrated by independent biological assays conducted by Hyperion Biotechnology.

^{**} United Kingdom began shipping products to Denmark in August 2005.

^{***} United Kingdom began shipping products to Germany in March 2006.

23

To help offset the decrease in net sales attributable to the questions surrounding our reformulated Advanced Ambrotose, we launched multi-faceted educational and marketing programs to further explain the science behind and the superior quality and potency of our reformulated product. Additionally, with the cooperation of our independent associates, we developed a multi-faceted marketing program, which includes a number of published articles, tours, other publications, marketing materials, web casts, and conference calls in an effort to further emphasize the high quality of our reformulated Advanced Ambrotose.

Our sales mix for the three and nine months ended September 30, was as follows:

				Dollar	and	For	the nine	mon	ths ende	d Dollar	and
	 ne three n Septemb 2005 (in mill	oer 3	60, 2006	ed percentag 2006 ove	8		Septem 2005 (in mi		2006	percentage 2006 ove	_
Consolidated product sales	\$ 72.5	\$		\$ 3.1	4.3%	\$	208.2	\$		\$ 19.2	9.2%
Consolidated pack sales	22.5		17.9	(4.6)	(20.4)%		69.0		61.9	(7.1)	(10.3)%
Consolidated other, including freight	5.2		6.1	0.9	17.3%		10.7		14.0	3.3	30.8%
Consolidated total net sales	\$ 100.2	\$	99.6	\$ (0.6)	(0.7)%	\$	287.9	\$	303.3	\$ 15.4	5.3%

Our total sales and sales mix can be influenced by any of the following:

changes in our sales prices;
changes in consumer demand;
changes in competitors products;
changes in economic conditions;
changes in regulations;
announcements of new scientific studies and breakthroughs;
introduction of new products;
discontinuation of existing products;
negative publicity; and

changes in our commissions and incentives programs.

24

Pack Sales

We sell starter packs to our new independent associates, which entitles the independent associate to purchase our products at wholesale prices. Members can also purchase starter packs, which entitles them to purchase our products at a discount from published retail prices. Depending on the type of pack purchased, a starter pack may include certain products, promotional and educational information, and policies and procedures. Independent associates can also purchase upgrade packs, entitling the independent associate to additional promotional materials and achievement of additional commissions and incentives. Our independent business-building associates also purchase annual renewal packs. Pack sales have a correlation to new and continuing independent associates and members who purchase our products. However, there is not necessarily a direct correlation between the change in the number of new independent associates purchasing packs and the amount of product sales because independent associates and members may consume different products at different consumption levels. The number of new and continuing independent associates and members who purchased our packs during the last 12-months ended September 30, 2005 and 2006 were as follows:

For the twelve months ended September 30, (revised*)

					Number and per	centage
Current Independent Associates and Members	2005	5	2006	1	change	
New	228,000	48.5%	208,000	38.9%	(20,000)	(8.8)%
Continuing	242,000	51.5%	328,000	61.1%	86,000	35.5%
Total	470,000	100%	536,000	100%	66,000	14.0%

^{*} In the third quarter 2005, we originally reported on our Form 10-Q, the split between new and continuing independent associates and members to be 219,000, 46.6%, and 251,000, 53.4%, respectively. The original calculation included a miscalculation in the allocation between new and continuing associates. However, the total number of associates was correctly reported at 470,000.

Overall, the number of independent associates and members increased by 14.0% as compared to the same period in 2005. We experienced a decrease in the number of new associates and members purchasing packs in each of North America, Australia, New Zealand, and the United Kingdom. We believe the decrease in new pack sales from new independent associates and members for both the three months and the nine months ended September 30, 2006 as compared to the same period in 2005, primarily related to the previously discussed challenges from our Advanced Ambrotose product. Additional actions we are taking to help increase the number of independent associates and members are as follows:

introduce in November 2006 PhytoMatrix, which contains a unique blend of plant-based minerals, all natural vitamin complexes, and standardized phytochemicals that we believe will be the first such product in our industry;

register our new preservative-free skin care products into all other markets in which we operate;

initiate additional incentives; and

explore new advertising tools to broaden our name recognition.

Pack sales associated with new independent associates and members and pack sales from continuing independent associates are as follows (in millions):

	For	For the three months ended September 30, Dollar and percentage			For the nine months ended September 30, Dollar and percentage				
	2005	2006	change	of pack sales	2005	2006	chang	e of pack sales	
New	\$ 15.7	\$ 11.5	\$ (4.2	(26.8)%	\$48.6	\$ 39.9	\$ (8	3.7) (17.9)%	
Continuing	6.8	6.4	(0.4	(5.9)%	20.4	22.0	1	.6 7.8%	
Total	\$ 22.5	\$ 17.9	\$ (4.0	(20.4)%	\$ 69.0	\$ 61.9	\$ (7	7.1) (10.3)%	

Product Sales

Overall product sales grew 4.3% and 9.2%, respectively, for the three months and nine months ended September 30, 2006 as compared to the same periods in 2005. The growth of product sales was fueled by introduction of FiberSlim in the United States in March 2006, the introduction of 7 preservative-free skin care products in Japan in May 2006, and the introduction of Undaria capsules in Australia and New Zealand in the summer of 2006. Introduction of these products increased our product sales by \$1.0 million for the three months ended September 30, 2006 and increased our product sales by \$1.8 million for the nine months ended September 30, 2006, each as compared to the same periods in 2005.

For the three months ended September 30, 2006, the remaining increase in existing product sales of \$2.1 million and for the nine months ended September 30, 2006, the remaining increase in product sales of \$17.4 million related to an increase in volume of products sold, which was partially attributable to an increase in the overall number of independent associates and members purchasing products.

Other Sales

Other sales pri	marily consist of the following:
	freight revenue charged to our independent associates and members;
	sales of promotional materials;
	training and event registration fees;
	monthly fees collected for Success Tracker , a customized electronic business-building and educational materials database for our independent associates that helps stimulate product sales and provide business management;
	a reserve for estimated sales refunds; and

a change in deferred revenue that primarily pertains to the timing of recognition of revenue for pack and product shipments. For the three months ended September 30, 2006, other sales increased by \$0.9 million as compared to the same period in 2005. The increase in other sales was composed of an increase of \$0.4 million for deferred revenue associated with the timing of revenue recognition and a decrease in sales refund reserves of \$0.6 million. This increase in other sales was partially offset by a decrease of \$0.1 million in training fees, associated with the timing of training events.

For the nine months ended September 30, 2006, other sales increased by \$3.3 million as compared to the same period in 2005. The increase was composed of an increase of \$1.4 million related to freight fees charged to customers and a decrease of \$2.3 million for deferred revenue associated with the timing of revenue recognition. This was partially offset by a decrease of \$0.4 million in sales of promotional materials partially due to the prior year s introduction of a new training DVD.

Cost of Sales

Cost of sales primarily consists of products purchased from third-party manufacturers, costs of promotional materials sold to our independent associates, in-bound freight, provisions for slow-moving or obsolete inventories, and costs associated with complementary shipped products. Our cost of sales as a percentage of net sales is affected by unit costs for purchased products and the mix of products and packs sold as product sales have higher gross margins than pack sales.

At September 30, 2006, inventories decreased by \$0.3 million, or 1.5%, to \$20.1 million as compared to \$20.4 million at September 30, 2005. The decrease in inventories consisted of a decrease of \$2.1 million in finished goods and promotional materials on hand related to the timing of

ordering inventory, partially offset by an increase of \$1.8 million in raw materials on hand associated with required purchase commitments. Our inventories turned at an annual rate of 2.9 times during the first nine months of 2006 as compared to 3.4 times during the first nine months of 2005. The decrease in inventory turnover is attributable to the increase in raw materials.

26

For the three months ended September 30, 2006 as compared to the same period in 2005, cost of sales decreased by a total of \$1.0 million, which was composed of a decrease of \$1.1 million in cost of sales and promotional materials, which was partially offset by a decrease of \$0.1 million in deferred costs associated with timing of revenue recognition. Cost of sales as a percentage of sales decreased by 0.9%, to 13.5%, which was primarily related to efficiencies in the supply chain process achieved through the use of more economical product components related to new technology in production of certain product components.

For the nine months ended September 30, 2006 as compared to the same period in 2005, cost of sales decreased by a total of \$0.4 million. The decrease was composed of a decrease of \$0.5 million in cost of sales and promotional materials and a decrease of \$0.3 million related to additional write offs in 2005 related to our original formulation of Advanced Ambrotose. This was partially offset by a decrease of \$0.3 million in deferred costs associated with timing of revenue recognition and an increase of \$0.1 million in shipping supplies related to the timing of ordering supplies. Cost of sales as a percentage of sales decreased by 0.9%, to 14.1%, which primarily related to efficiencies in the supply chain process achieved through the use of more economical product components related to new technology in production of certain product components.

Commissions and Incentives

Commissions and incentives are heavily dependent on the sales mix and types of incentives offered and generally run between 41% to 46% as a percentage of net sales. Commissions are earned by independent associates in accordance with our global associate career and compensation plan. Incentives are contests and travel incentives offered to our independent associates. Commissions and incentives are calculated using commissionable net sales, which consist of finished product and pack sales and are based on the following criteria:

the independent associate s earned placement and position within our overall global career and compensation plan;

specific timing and sales volume of an independent associate s direct and indirect commissionable sales; and

the achievement of certain sales levels.

Our unique global associate career and compensation plan allows new and existing independent associates to build their individual global networks by expanding their existing downlines into international markets rather than requiring them to establish new downlines to qualify for commissions and incentives within each country of operation.

Commissions

For the three months ended September 30, 2006, commissions decreased by 2.1%, or \$0.9 million, to \$43.0 million as compared to \$43.9 million for the same period in 2005. The decrease in commissions primarily related to the timing of the qualification period for our travel incentives. For the nine months ended September 30, 2006, commissions increased by 4.3%, or \$5.3 million, to \$130.0 million as compared to \$124.7 million in 2005. The increase in commissions primarily related to the mix of packs and products sold.

For the three months ended September 30, 2006, commissions as a percentage of net sales decreased to 43.2% from 43.8% for the same three month period of 2005. For the nine months ended September 30, 2006, commissions as a percentage of net sales decreased to 43.0% from 43.3% for the same period in 2005. The decrease related to the shift in mix of packs and products sold.

Incentives

Each year, we offer new travel incentives and contests that are designed to stimulate both pack and product sales. We accrue costs associated with the travel incentives during the months when independent associates qualify to win the trips. In 2006, the qualification period for the travel incentives started in mid January and ended in May, as compared to 2005 when the travel incentives began in mid March and ended in July. As a result of the shift in qualification period, a larger portion of the costs for the travel incentives for 2006 was accrued in the first quarter of 2006 as compared to the same period in 2005.

27

For the three months ended September 30, 2006, the cost of incentives increased by 80.0%, or \$0.4 million, to \$0.9 million as compared to \$0.5 million for the same period in 2005. This increase was due to new summer incentives initiated this year. For the nine months ended September 30, 2006, the cost of incentives increased by 15.2%, or \$0.7 million, to \$5.3 million as compared to \$4.6 million for the same period in 2005.

For the three months ended September 30, 2006, the cost of incentives, as a percentage of net sales, increased to 0.9% as compared to 0.5% for the same period in 2005. For the nine months ended September 30, 2006, the cost of incentives, as a percentage of net sales increased to 1.7% as compared to 1.6% for the same period in 2005. This increase was due to new summer incentives initiated this year.

Gross Profit

For the three months and nine months ended September 30, 2006, gross profit increased as compared to the same period in 2005. The increase in gross profit was the result of a shift in the mix of pack and product sales, the introduction of new incentives in the summer, and efficiencies gained in the supply chain process.

Selling and Administrative Expenses

Selling and administrative expenses include a combination of both fixed and variable expenses. These expenses consist of compensation and benefits for employees, temporary and contract labor, outbound shipping and freight, and marketing-related expenses, such as monthly magazine development costs and costs related to hosting our corporate-sponsored events.

For the three months ended September 30, 2006, selling and administrative expenses increased by \$0.4 million, which primarily consisted of the following:

a net increase of \$0.3 million in compensation and compensation-related costs, which included an increase in payroll and payroll-related costs of \$1.3 million that was partially offset by a decrease in temporary and contract labor of \$0.6 million and capitalizing \$0.4 million in compensation costs associated with our internally-developed software project;

recording \$0.2 million related to compensation expense for unvested stock options granted prior to December 31, 2005 and granting stock options after December 31, 2005, as required by FAS 123R; and

a decrease of \$0.1 million in freight-out and third party warehouse costs associated with a decrease in sales. For the nine months ended September 30, 2006, selling and administrative expenses increased \$4.0 million, which primarily consisted of the following:

a net increase of \$2.8 million in compensation and compensation-related costs, which included a \$4.6 million increase in payroll and payroll related costs that was partially offset by a decrease in temporary and contract labor of \$0.2 million and capitalizing \$1.6 million in compensation-related costs associated with our internally-developed software project;

an increase of \$0.6 million in marketing-related expenses associated with additional activities related to marketing campaigns including name recognition activities;

recording \$0.5 million related to compensation expense for unvested stock options granted prior to December 31, 2005 and granting stock options after December 31, 2005; and

an increase of \$0.1 million in freight-out and third party warehouse costs associated with a change in net sales volume and an increase in fuel costs from third-party vendors.

28

Other Operating Costs

Other operating costs generally include travel, accounting/legal/consulting fees, royalties, credit card processing fees, banking fees, off-site storage fees, utilities, depreciation, and other miscellaneous operating type expenses. Generally, changes in other operating costs are associated with the changes in our net sales; however, specific changes in other operating costs include the following:

Travel

For the three months ended September 30, 2006, travel expenses increased by \$0.2 million to \$1.5 million as compared to \$1.3 million for the third quarter of 2005. For the nine months ended September 30, 2006, travel expenses increased by \$0.7 million to \$4.8 million as compared to \$4.1 million for the same period in 2005. Travel expenses increased due to additional trips by our management to attend corporate-sponsored events, additional support and training provided to our international offices, and costs associated with our internally-developed software project and planned international growth.

Accounting, legal, and consulting fees

For the three months ended September 30, 2006, accounting, legal, and consulting fees decreased by \$0.7 million to \$2.6 million as compared to \$3.3 million for the third quarter of 2005. This decrease was composed of a reduction of \$0.4 million in activity related to legal fees associated with ongoing lawsuits and regulatory matters and a decrease in consulting fees of \$0.4 million primarily related to capitalizing costs associated with our internally-developed software project. These decreases were partially offset by an increase of \$0.1 million in accounting fees related to tax related services.

For the nine months ended September 30, 2006, accounting, legal, and consultant-related fees decreased by \$0.9 million to \$7.8 million as compared to \$8.7 million for the same period in 2005. The decrease was composed of a reduction of \$0.5 million in accounting fees associated with gaining operational efficiencies in resources used to test internal controls and hiring additional accounting personnel. In addition, accounting, legal, and consultant-related fees decreased by \$0.4 million due to a reduction of legal fees associated with ongoing lawsuits and regulatory matters.

Royalties

For the three months ended September 30, 2006, royalty expense decreased by \$0.6 million to \$0.2 million as compared to \$0.8 million for the third quarter of 2005. For the nine months ended September 30, 2006, royalty expense decreased by \$2.5 million to \$0.7 million as compared to \$3.2 million for the same period in 2005. The decrease in royalty expense related to fully accruing future royalties associated with the long-term post-retirement royalty agreement with Dr. Bill McAnalley in the third quarter of 2005.

Credit card processing fees

For the three months ended September 30, 2006, credit card processing fees increased by \$0.3 million to \$2.1 million as compared to \$1.8 million for the third quarter in 2005. The increase in credit card processing fees is the result of an increase in customers using credit cards. For the nine months ended September 30, 2006, credit card processing fees increased by \$0.5 million to \$6.4 million as compared to \$5.9 million for the same period in 2005. The increase in credit card processing fees is the result of an increase in net sales and increase in customers using credit cards.

Depreciation and repair and maintenance expenses

For the three months ended September 30, 2006, depreciation and repair and maintenance expenses increased by \$0.5 million to \$1.9 million as compared to \$1.4 million for the third quarter in 2005. For the nine months ended September 30, 2006, depreciation and repair and maintenance expenses increased by \$1.2 million to \$5.2 million as compared to \$4.0 million for the same period in 2005. The increase in depreciation expense primarily related to capitalization of costs incurred related to Phase I of our internally-developed software project, which was put into service in 2005. The increase in repair and maintenance expenses primarily related to non-capitalizable costs incurred with corporate building renovation.

Research and development costs

For the three months ended September 30, 2006, research and development costs increased by \$0.7 million to \$0.9 million as compared to \$0.2 million for the third quarter in 2005. For the nine months ended September 30, 2006, research and development costs increased by \$1.1 million to \$1.4 million as compared to \$0.3 million for the same period in 2005. The increase was directly related to the development of our skin care formulation and other research and development activities.

Other miscellaneous operating expenses

The remaining miscellaneous operating expenses are primarily variable in nature and relate directly to the change in net sales. Variable costs included in other miscellaneous operating expenses consist of bank charges, telephone, postage, insurance, and offsite storage fees. For the three months ended September 30, 2006, other miscellaneous operating expenses increased by \$1.2 million to \$4.8 million as compared to \$3.6 million in 2005. For the nine months ended September 30, 2006, other miscellaneous operating expenses increased by \$3.0 million to \$13.4 million as compared to \$10.4 million for the same period in 2005.

Interest Income

We maintain interest-bearing accounts for certain of our cash equivalents and investments. For the three months ended September 30, 2005, interest income increased by \$0.1 million to \$0.6 million as compared to \$0.5 million for the same period in 2005. For the nine months ended September 30, 2006, interest income increased by \$0.5 million to \$1.8 million as compared to \$1.3 million for the same period in 2005. The increase in interest income related to the increase in the average balance and an improvement of our average yield on investments.

Other Income (Expense), Net

Other income (expense), net consists of foreign currency transaction gains and losses related to translating our foreign subsidiaries—assets, liabilities, revenues, and expenses to the United States dollar and translating the United States parent—s monetary accounts held in foreign locations using current and weighted-average currency exchange rates. Net foreign currency transaction gains and losses are the result of the United States dollar fluctuating in value against foreign currencies.

30

Provision for Income Taxes

Provision for income taxes include current and deferred income taxes for both our domestic and foreign operations. Our statutory income tax rates by jurisdiction are as follows:

Country	For the three and nine months ended September 30, 2005	For the three and nine months ended September 30, 2006
United States*	38%	37.5%
Australia	30%	30%
United Kingdom	30%	30%
Japan	42%	42%
Republic of Korea	25%	27.5%
Taiwan (began operations in June 2005)	25%	25%

^{*} For 2005 and 2006, the United States statutory income tax rates include a federal income tax rate of 35% and an average state income tax rate of 3.0% for 2005 and 2.5% for 2006.

Approximately one-third of our total consolidated net sales are derived from our international operations and subject to the country-specific applicable statutory income tax rates. Income from our international operations is subject to taxation in the countries in which we operate. Although we may receive foreign tax credits that would reduce the total amount of income taxes owed in the United States, we may not be able to fully utilize our foreign tax credits in the United States.

We use the recognition and measurement provisions of Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes (FAS 109) to account for income taxes. The provisions of FAS 109 require companies to record a valuation allowance when the *more likely than not* criteria for realizing net deferred tax assets cannot be met. Furthermore, the weight given to the potential effect of such evidence should be commensurate with the extent to which it can be objectively verified. As a result, we review the operating results, as well as all of the positive and negative evidence related to realizability of such deferred tax assets to evaluate the need for a valuation allowance in each tax jurisdiction. As of September 30, 2006 and 2005, we maintain a valuation allowance for deferred tax assets in the Republic of Korea and Taiwan totaling \$0.7 million and \$0.3 million, respectively. We believe the *more likely than not* criteria for recognition and realization purposes, as defined in FAS 109, has not been met.

The dollar amount of the provisions for income taxes has increased because of an increase in our profitability and a change in the mix of taxable income. For the three months ended September 30, 2006, our effective tax rate decreased to 24.0% from 32.6% for the third quarter in 2005. For the nine months ended September 30, 3006, our effective tax rate decreased to 31.7% from 36.7% for the prior year period. The decrease in our effective tax rate primarily related to an increase in favorable permanent differences and tax credits, as well as a change in the mix of taxable income between countries, compared to the three and nine months ended September 30, 2005.

Net Income and Earnings Per Share

Net income primarily increased as a result of an increase in gross profit and a reduction of our effective income tax rate. Diluted earnings per share for the three months ended September 30, 2006, increased by 12.5%, or \$0.04 per share, to \$0.36 per share for 2006 as compared to \$0.32 per share for the same period in 2005. For the nine months ended September 30, 2006, diluted earnings per share increased by 29.0%, or \$0.20 per share, to \$0.89 per share for 2006 as compared to \$0.69 per share for the same period in 2005. The increase in diluted earnings per share primarily related to an increase in gross profit and a reduction in our effective income tax rate.

Our quarterly cash dividend for 2006 increased to \$0.08 per share as compared to \$0.07 per share for 2005. We have declared and paid the following dividends:

Date dividends declared	Date dividends paid	Total amount of dividends	Dividend paid per common share
November 2004	January 2005	\$1.9 million	\$0.07
March 2005	April 2005	\$1.9 million	\$0.07
June 2005	July 2005	\$1.9 million	\$0.07
September 2005	October 2005	\$1.9 million	\$0.07
November 2005	January 2006	\$2.1 million	\$0.08
March 2006	April 2006	\$2.1 million	\$0.08
June 2006	July 2006	\$2.1 million	\$0.08
October 2006	October 2006	\$2.1 million	\$0.08

Liquidity and Capital Resources

Our principal use of cash is to pay for operating expenses, including commissions and incentives, capital assets, inventory purchases, funding international expansion, and payment of quarterly dividends. We generally fund our business objectives, operations, and expansion of our operations through our net cash flows from operations rather than incurring long-term debt, and we plan to continue to fund our needs through our net cash flows from operations. We have approximately \$39.9 million in cash equivalents and \$25.4 million in investments which can be used along with our normal cash flows from operations to fund any unanticipated shortfalls in our future cash flows.

Cash and Cash Equivalents and Investments

For the nine months ended September 30, 2006, we continue to preserve our strong cash and investment position. Our investment balance increased by \$8.1 million, or 46.8%, to \$25.4 million from \$17.3 million at December 31, 2005. Our cash and cash equivalents decreased by 28.9%, or \$16.3 million, to \$39.9 million from \$56.2 million at December 31, 2005. The decreases in cash and cash equivalents related to the purchase of additional investments, funding additional restricted cash, and funding capital asset purchases.

Working Capital

For the nine months ended September 30, 2006, our working capital decreased by 22.6%, or \$8.6 million, to \$29.5 million from \$38.1 million at December 31, 2005. This decline in working capital primarily related to the use of current assets to fund capital assets and purchase long-term investments. Although we can give no assurances, we believe our working capital will remain relatively unchanged as we monitor our existing cash flow needs with our current long term investment strategy.

Our net consolidated cash flows consist of the following:

	For the nine n	nonths ended
	Septem	ber 30,
Provided by (used in):	2005	2006
Operating activities	\$ 27.6 million	\$ 23.4 million
Investing activities	\$ (11.6 million)	\$ (29.2 million)
Financing activities	\$ (10.1 million)	\$ (9.9 million)

Operating Activities

For the nine months ended September 30, 2006, our net operating activities provided cash of \$23.4 million compared to providing cash of \$27.6 million for the same period of 2005. Net income adjusted for noncash activities provided cash of \$33.9 million as compared to providing cash of \$24.2 million for the same period of 2005. For the nine months ended September 30, 2006, our working capital accounts used \$10.4 million in net operating cash flow as compared to providing \$3.4 million in net operating cash flow for the same period of 2005. Our working capital accounts include increases in receivables, inventories, prepaid expenses, and deferred revenues, and a reduction in cash, payables and accrued expenses. In addition, our decrease in working capital included a shift of short term investments into long-term investments Although we can give no assurances, we anticipate our operating activities will continue to provide cash for our operating needs in the future.

Investing Activities

Our net investing activities for the nine months ended September 30, 2006, used cash of \$29.2 million compared to using cash of \$11.6 million for the same period of 2005. For the first nine months of 2006, we purchased \$20.3 million in capital assets and investments compared to purchasing \$9.2 million in capital assets and investments for the same period of 2005. This use of cash in 2005 was partially offset by decreasing restricted cash by \$0.3 million and the timing of holding security deposits of \$2.5 million for our annual travel incentives.

Capital asset purchases include capitalized costs associated with our internally-developed software system. In 2004, we substantially completed the development of Phase I of this project, and in 2005, we began configuring Phase II. We originally anticipated to have substantially completed this project in the third quarter of 2006. However, we have extended the deadline for completion to April 2007 in order to add additional functionality and fully test the configuration and integration of this large-scaled internally developed software project. The postponement is projected to increase the total estimated cost of this project from \$31.0 million to \$35.0 million A recap of the total expected costs associated with this internally-developed software system is as follows:

	Capitalized co	sts Non-	Non-capitalized costs		l estimated costs
2004	\$ 3.1 milli	on \$	0.5 million	\$	3.6 million
2005	\$ 9.3 milli	on \$	2.3 million	\$	11.6 million
Nine months ended September 30, 2006	\$ 10.5 milli	on \$	1.7 million	\$	12.2 million
Anticipated costs to be incurred for the remainder of 2006 and early 2007	\$ 5.6 milli	ion \$	2.0 million	\$	7.6 million
Total costs of project	\$ 28.5 milli	ion \$	6.5 million	\$	35.0 million

As a result of adding additional functionality to our internally-developed software, we anticipate reducing the amount of capital assets purchased in the future from \$2.0 million \$4.0 million \$1.0 million \$3.0 million for use in our expansion of our corporate facilities and planned international expansion.

Financing Activities

For the nine months ended September 30, 2006, we used cash of \$9.9 million to fund our financing activities and used cash of \$10.1 million for the same period of 2005. For the nine months ended September 30, 2006, we used cash of \$4.3 million to fund quarterly cash dividend payments to our shareholders and used \$7.0 million in cash to purchase our common stock in the open market. This use of cash was partially offset by receiving \$0.9 million in cash proceeds from option holders exercising their stock options and recording a tax benefit related to stock options exercised of \$0.5 million.

For the nine months ended September 30, 2005, we used cash of \$5.7 million to fund quarterly cash dividends to our shareholders and purchased \$5.0 million of our common stock in the open market. In 2006, we purchased \$7.0 million of our common stock in the open market and we plan to continue to purchase our stock. As of September 30, 2006, we had 196,124 additional shares available from the previously announced, board-approved plan, which can be used by the Company to purchase our common stock. In addition, in August 2006, the Board authorized us to purchase up to \$20 million of our common stock in the open market. Such purchases would use between \$22.5 million and \$23.5 million of our cash.

General Liquidity and Cash Flows

We continue to generate positive cash flows from our operations and believe our existing liquidity and cash flows from operations are adequate to fund our normal expected future business operations, fund our estimated payments of cash dividends, fund the repurchase of our common stock in the open market, fund international expansion costs, and pay costs associated with implementing our new fully-integrated computer system for the next 12 to 24 months. However, if our existing capital resources or cash flows become insufficient to meet current business plans, projections, and existing capital requirements, we would be required to raise additional funds, which may not be available on favorable terms, if at all.

We do not have any special-purpose entity arrangements, nor do we have any off balance-sheet arrangements. However, we do maintain certain future commitments associated with various agreements and contracts. As of September 30, 2006, our future commitments and obligations are as follows:

funding various operating leases for building and equipment rental of \$14.2 million through 2017;

funding various supply agreements to purchase raw materials of \$8.8 million through 2016;

funding an estimated \$3.0 million of the long-term post-employment royalties payable to Dr. McAnalley through 2015;

funding a total of \$2.6 million for non-cancellable employment agreements through December 2007, with Mr. Caster, Mr. Persinger, Mr. Price, Mr. Fenstermacher, Mr. O Day, and Mr. Clark, who are executive officers of the Company; and

funding cash donations of \$0.2 million in 2006 to MannaRelief, a non-profit 501(c)(3) charity.

Recent Accounting Pronouncements

FAS 157. In September 2006, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 157, Fair Value Measurements , (FAS 157). The provisions of FAS 157 define fair value, establish a framework for measuring fair value in generally accepted accounting principals, and expand disclosures about fair value measurements. The provisions of FAS 157 are effective for fiscal years beginning after November 15, 2006. We do not believe the adoption of FAS 157 will have a significant effect on our consolidated financial position, results of operations, or cash flows.


FAS 158. In September 2006, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 158, Employer's Accounting for Defined Benefit Pension and Other Postretirement Plans, an amendment of FASB Statements No. 87, 88, 106, and 132R, (FAS 158). Under the provisions of FAS 158, a company is required to recognize in its statement of financial condition the funded status of its defined benefit postretirement plans, measured as the difference between the fair value of the plan assets and the benefit obligation. FAS 158 also requires a company to recognize changes in the funded status of a defined benefit postretirement plan within accumulated other comprehensive income, net of tax, to the extent such changes are not recognized in earnings as components of periodic net benefit cost. FAS 158 is effective as of the end of the fiscal year ending after December 15, 2006. We maintain a Defined Benefit Plan for our Japan subsidiary and are currently assessing the impact of the adoption of this statement to our consolidated financial position, results of operations, or cash flows.

FIN 48. In July 2006, the Financial Accounting Standards Board issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109, (FIN 48). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an entity s financial statements in accordance with FAS 109 and prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Additionally, FIN 48 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006, with early adoption permitted. We currently are evaluating whether the adoption of FIN 48 will have a material effect on our consolidated financial position, results of operations, or cash flows.

SAB 108. In September 2006, the United States Securities and Exchange Commission issued Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements When Quantifying Misstatements in Current Year Financial Statements , (SAB 108). SAB 108 provides interpretive guidance on how the effects of the carryover or reversal of prior year misstatements should be considered in quantifying a current year misstatement. SAB 108 is effective for fiscal years ending after November 15, 2006. We do not believe the adoption of SAB 108 will have a material impact on our consolidated financial position, results of operations, or cash flows.

Forward-Looking Statements

Certain disclosures and analyses included in this report, including information incorporated by reference, includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995 that are subject to various risks and uncertainties. Opinions, forecasts, projections, guidance, or statements other than statements of historical fact are considered forward-looking statements. These statements reflect our current views about future events and/or financial performance. Forward-looking statements are subject to certain events, risks, and uncertainties that may be outside our control. Some of these forward-looking statements include statements regarding:




the outcome of new or existing regulatory and litigation matters; and

other assumptions described in this report underlying such forward-looking statements.

35

Actual results and developments could materially differ from those expressed in or implied by such statements due to a number of factors, including:



conduct of our independent associates;

any impact of competition, competitive products, and pricing;

the political, social, and economic climate in which we conduct our operations; and

the risk factors described in this report, as well as other reports we have filed with the United States Securities and Exchange Commission.

Forward-looking statements generally can be identified by the use of phrases or terminology such as may, will, should, could, expects, in the future, or continues or oth anticipates, believes, estimates, approximates, predicts, potential, projects, the negative of such terms and other comparable terminology. Similarly, descriptions of our objectives, plans, strategies, targets or beliefs contained herein are also considered forward-looking statements. If one or more of these risks or uncertainties materialize, or if any underlying assumption proves incorrect, actual results may vary materially from those anticipated, expected, or projected. Such forward-looking statements reflect our current views with respect to future events and are subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, growth strategy, and liquidity. All subsequent written and oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by this paragraph. A detailed discussion of risks is included, under the caption Risk Factors in our Form 10-K, filed on March 16, 2006. We do not undertake any obligation to update or revise any of our forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned when considering these forward-looking statements to keep in mind these risks and uncertainties and any other cautionary statements in this report since all of the forward-looking statements contained herein speak only as of the date of this report.

36

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We do not engage in trading market risk sensitive instruments and do not purchase investments as hedges or for purposes other than trading that are likely to expose us to certain types of market risk, including interest rate, commodity price, or equity price risk. Although we have some investments, we believe there has been no material change in our exposure to interest rate risk. We have not issued any debt instruments, entered into any forward or futures contracts, purchased any options, or entered into any swap agreements.

We are exposed to certain other market risks, including changes in currency exchange rates as measured against the United States dollar. The change in value of the United States dollar measured against foreign currency may affect our consolidated financial results, and as such, changes in foreign currency exchange rates could positively or negatively affect our results as expressed in United States dollars. For example, when the United States dollar strengthens against foreign currencies in which our products are sold or weakens against foreign currencies in which we may incur costs, our consolidated net sales and/or related costs and expenses could be adversely affected.

We believe inflation has not had a material impact on our consolidated operations or profitability. We expanded into Canada in 1996, into Australia in 1998, into the United Kingdom in 1999, into Japan in 2000, into New Zealand in 2002, into the Republic of Korea in 2004, into Taiwan and Denmark in 2005, and into Germany in 2006. Our United States operation services shipments to Canada, while our Australian operation services shipments to New Zealand, and our United Kingdom operation services shipments to Denmark and Germany. We translate our revenues and expenses in certain foreign markets using either a current (spot) rate or weighted-average rate.

We believe we maintain policies, procedures, and internal processes that help monitor any significant market risks and we do not use any financial instruments to manage our exposure to such risks. We assess the sensitivity of our earnings and cash flows to variability in currency exchange rates by applying an appropriate range of potential rate fluctuations to our assets, obligations, and projected transactions denominated in foreign currencies.

We caution that we cannot predict with any certainty our future exposure to such currency exchange rate fluctuations or the impact, if any, such fluctuations may have on our future business, product pricing, operating expenses, and on our consolidated financial position, results of operations, or cash flows. However, to combat such market risk, we believe we closely monitor our exposure to currency fluctuations. The foreign currencies in which we currently have exposure to foreign currency exchange rate risk include currencies in Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, and Germany. The current (spot) rate, weighted-average currency exchange rates, and the low and high of such currency exchange rates as compared to the United States dollar, for each of these countries as of and for the nine months ended September 30, 2006 were as follows:

			Weighted-	
Country (foreign currency name)	Low	High	Average	Spot
Australia (Dollar)	\$ 0.70440	\$ 0.77580	\$ 0.74795	\$ 0.74680
Canada (Dollar)	\$ 0.85360	\$ 0.91060	\$ 0.88318	\$ 0.89790
Denmark (Krone)	\$ 0.15850	\$ 0.17000	\$ 0.16690	\$ 0.17000
Germany (Euro)	\$ 1.18400	\$ 1.26880	\$ 1.24498	\$ 1.26880
Japan (Yen)	\$ 0.00841	\$ 0.00912	\$ 0.00864	\$ 0.00848
New Zealand (Dollar)	\$ 0.59620	\$ 0.69920	\$ 0.64180	\$ 0.65350
Republic of Korea (Won)	\$ 0.00100	\$ 0.00111	\$ 0.00106	\$ 0.00107
Taiwan (Dollar)	\$ 0.03023	\$ 0.03189	\$ 0.03086	\$ 0.03023
United Kingdom (British Pound)	\$ 1.72280	\$ 1.90840	\$ 1.81842	\$ 1.87260

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chairman of the Board and Chief Executive Officer (principal executive officer) and our Chief Financial Officer (principal financial officer) have concluded, based on their evaluation as of the end of the period covered by this report, that the Company s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in its reports filed or submitted under the Securities Exchange Act of 1934, as amended (as defined in Exchange Act Rules 13(a) and 15(d)-15(e)), is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission s rules and forms and include controls and procedures designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company s management, including its principal executive and financial officers, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the nine months ended September 30, 2006, there were no changes in our internal control over our financial reporting that we believe materially affected, or are reasonably likely to materially affect our internal control over our financial reporting. However, in April 2007, we plan to complete the implementation of Phase II of our internally-developed software project, which will complete the integration of our global operational systems with our financial system into the Oracle/JD Edwards Enterprise One System. We do not anticipate the completion of the implementation of the fully-integrated system will have a material affect on our internal control over our financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We have been sued in three securities class action lawsuits in the United States District Court for the District of New Mexico, which remain pending.

First, on August 1, 2005, Mr. Jonathan Crowell filed a putative class action lawsuit against the Company and Mr. Samuel L. Caster, our Chief Executive Officer, on behalf of himself and all others who purchased or otherwise acquired our common stock between August 10, 2004 and May 9, 2005, inclusive, and who were damaged thereby.

Second, on August 30, 2005, Mr. Richard McMurry filed a class action lawsuit against the Company, Mr. Caster, Mr. Terry L. Persinger, our President and Chief Operating Officer, and Mr. Stephen D. Fenstermacher, our Chief Financial Officer.

Third, on September 5, 2005, Mr. Michael Bruce Zeller filed a class action lawsuit against the Company, Mr. Caster, Mr. Persinger, and Mr. Fenstermacher.

The allegations in these class action lawsuits are substantially identical. The complaints allege we violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5 thereunder, claiming that defendants artificially inflated the value of our common stock by knowingly allowing independent contractors to recklessly misrepresent the efficacy of our products during the purported class period.

On December 12, 2005, the Court granted a motion to consolidate the three putative class action lawsuits into one civil action styled In re Mannatech, Incorporated Securities Litigation. Also, on January 4, 2006, the Court entered an order appointing The Mannatech Group, consisting of Mr. Austin Chang, Ms. Naomi S. Miller, Mr. John C. Ogden, and the Plumbers and Pipefitters Local 51 Pension Fund, as lead plaintiffs and appointing the law firms Lerach Coughlin Stoia Geller Rudman & Robbins LLP, as lead counsel, and Freedman Boyd Daniels Hollander & Goldberg, P.A., as liaison counsel, for the putative class. On March 3, 2006, the lead plaintiffs filed an amended consolidated class action complaint.

38

Our motion to transfer venue to the United States District Court for the Northern District of Texas, Dallas Division, in the consolidated class action lawsuits remains pending before the Court. Both sides have submitted briefings on the issue of transfer, and we filed a Notice of Completion of Briefing with the Court on June 28, 2006. We anticipate the Court will rule on this motion in the coming months.

We have also been sued in three shareholder derivative lawsuits, which remain pending.

First, on October 18, 2005, a shareholder derivative lawsuit was filed by Norma Middleton, Derivatively and on Behalf of Nominal Defendant, Mannatech, Incorporated against Samuel L. Caster, Terry L. Persinger, Donald A. Buchholz, J. Stanley Fredrick, Gerald E. Gilbert, Alan D. Kennedy, Marlin Ray Robbins, and Patricia A. Wier, in the United States District Court for the Northern District of Texas, Dallas Division.

Second, on January 11, 2006, a shareholder derivative action was filed by Kelly Schrimpf, Derivatively and on Behalf of Nominal Defendant Mannatech, Incorporated against Samuel L. Caster, Terry L. Persinger, Steven W. Lemme, and Stephen D. Fenstermacher in the 162nd District Court of Dallas County, Texas.

Third, on January 13, 2006, a shareholder derivative action was filed by Frances Nystrom, Derivatively and on Behalf of Nominal Defendant Mannatech, Incorporated against Samuel L. Caster, Terry L. Persinger, Stephen D. Fenstermacher, John Stuart Axford, J. Stanley Fredrick, Gerald E. Gilbert, Alan D. Kennedy, Marlin Ray Robbins, Patricia A. Wier, and Donald A. Buchholz in the United States District Court for the Northern District of Texas, Dallas Division.

Each of these shareholder derivative lawsuits makes allegations similar to the allegations of the shareholder class action litigation described above.

Our independent directors appointed a Special Litigation Committee to review these matters and determine the proper corporate response. This review was completed on August 26, 2006 and the Special Litigation Committee issued its report, determining that it is in the best interests of Mannatech to dismiss the derivative lawsuits. Statements by us to this effect were filed with the courts in the respective derivative cases on September 13, 2006.

The Schrimpf state court lawsuit is presently stayed pending the final disposition of the Middleton federal lawsuit, the first-filed derivative action. Our motions to stay in the Middleton and Nystrom federal court lawsuits, pursuant to Texas Business Corporation Act art. 5.14, have been denied by the Court. Our motion to consolidate the Middleton and Nystrom lawsuits remains pending, as does a separate motion to consolidate filed by Middleton on August 17, 2006. Competing motions to appoint lead plaintiff and lead counsel have also been filed by both Middleton and Nystrom. These motions were filed August 17, 2006, and September 6, 2006, respectively, and remain pending.

We have reached an agreement with each of the derivative plaintiffs counsel, as well as with counsel for the lead plaintiffs in the consolidated securities class action, to explore an early mediation. Therefore the parties in the derivative suits have filed agreed motions to extend for 90 days the date by which the defendants must file their answer, motion to dismiss, or otherwise file a responsive pleading. These motions are pending before the Court.

Plaintiffs in the consolidated putative class actions and in the shareholder derivative actions seek an unspecified amount of compensatory damages, interest and costs, including legal and expert fees.

In response to these actions, we continue to work with our experienced securities litigation counsel to vigorously defend us and our officers and directors. It should be noted that a court must certify a class before a case can proceed as a class action lawsuit and that the determination has not been made in the consolidated securities cases. We believe these types of repetitive lawsuits (seeking class action status) are common in today s litigious society and many reputable companies have successfully defended themselves against such litigation. It is not possible at this time to predict whether we will incur any liability, or to estimate the damages or the range of damages, if any, that we might incur in connection with any of these above mentioned securities and derivative lawsuits.

On March 16, 2006, we filed a patent infringement lawsuit against Glycobiotics International, Inc. for alleged infringement of our utility U.S. Patent No. 6,929,807 (Compositions of Plant Carbohydrates as Dietary Supplements) in the United States District Court of the Northern District of Texas. We sued Glycobiotics to cease the manufacture, sale, and use of its glyconutritional product marketed under the brand name Glycomannan and for alleged unfair competition due to false and misleading statements. In April 2006, Glycobiotics filed its response and asserted various affirmative defenses. We intend to vigorously prosecute the case. The case is currently in the initial phases of discovery, and we expect a trial date in 2007.

On May 5, 2006, we also filed a patent infringement lawsuit against Techmedica Health Inc. for alleged infringement of our utility U.S. Patent No. 6,929,807 (Compositions of Plant Carbohydrates as Dietary Supplements) in the United States District Court of the Northern District of Texas, Dallas Division. We sued Techmedica Health to cease the manufacture, sale, and use of its glyconutritional product marketed under the brand name Nutratose and for alleged unfair competition due to false and misleading statements. In June 2006, we filed an objection to the change in venue filed by Techmedica Health Inc. The court agreed with our position and denied Techmedica's motion to transfer on August 3, 2006. We intend to vigorously prosecute the case. The case is currently in the discovery phase and we expect a trial date in early 2008.

We also have several pending claims incurred in the normal course of business. In the opinion of management, such claims can be resolved without any material affect on our consolidated financial position, results of operations, or cash flows.

We maintain certain liability insurance in amounts we believe are adequate. However, certain costs of defending lawsuits, such as those below the insurance deductible amount, are not covered by or only partially covered by our insurance policies, and our insurance carriers could refuse to cover certain of these claims in whole or in part.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2005, which could materially affect our business and/or our consolidated financial position, results of operations, and cash flows. The risks described in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be insignificant also may become materially adverse or may affect our business in the future and/or our consolidated financial position, results of operations, or cash flows.

40

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On June 30, 2004, our Board of Directors authorized us to repurchase, in the open market, up to 5% of our outstanding shares, or approximately 1.3 million shares, of our common stock to help manage any dilutive effects of our common stock in the open market. On August 28, 2006, our Board of Directors approved a second program permitting us to purchase up to \$20 million of our outstanding common shares. As of September 30, 2006, we have purchased the following number of shares of our common stock in the open market:

		Total number of shares					
			purchased as part of	Maximum number of shares that may yet be			
Total number of	Average price paid		Average price paid		publicly announced	purchased under the	
shares purchased	per share		per share		plans or programs	plans or programs	
190,850	\$	15.71	190,850				
182,626	\$	10.95	182,626				
207,023	\$	9.66	207,023				
73,955	\$	13.52	73,955				
253,289	\$	11.84	253,289				
144,840	\$	13.81	144,840				
68,861	\$	14.51	68,861				
1.121.444	\$	12.48	1.121.444	196.124			
	shares purchased 190,850 182,626 207,023 73,955 253,289 144,840	shares purchased permitted 190,850 \$ 182,626 \$ 207,023 \$ 73,955 \$ 253,289 \$ 144,840 \$ 68,861 \$	shares purchased per share 190,850 \$ 15.71 182,626 \$ 10.95 207,023 \$ 9.66 73,955 \$ 13.52 253,289 \$ 11.84 144,840 \$ 13.81 68,861 \$ 14.51	Total number of Average price paid publicly announced shares purchased per share plans or programs 190,850 \$ 15.71 190,850 182,626 \$ 10.95 182,626 207,023 \$ 9.66 207,023 73,955 \$ 13.52 73,955 253,289 \$ 11.84 253,289 144,840 \$ 13.81 144,840 68,861 \$ 14.51 68,861			

Item 3. Defaults Upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

None.

Item 5. Other Information

None.

41

Item 6. Exhibits

Incorporated by Reference

Exhibit

Number	Exhibit Description	Form	File No.	Exhibit (s)	Filing Date
3.1	Amended and Restated Articles of Incorporation of Mannatech, dated May 19, 1998.	S-1	333-63133	3.1	October 28.1998
3.2	Fourth Amended and Restated Bylaws of Mannatech, dated August 8, 2001.	8-K	000-24657	99.1	August 22, 2001
4.1	Specimen Certificate representing Mannatech s common stock, par value \$0.0001 per share.	S-1	333-63133	4.1	October 28, 1998
10.1	Consulting Agreement between Bettina S. Simon and Mannatech, dated June 11, 2006.	8-K	000-24657	99.1	June 12, 2006
10.2	Employment Agreement between Stephen D. Fenstermacher and Mannatech, dated June 15, 2006.	8-K	000-24657	99.1	June 19, 2006
10.3	Employment Agreement between Terence O Day and Mannatech, dated June 27, 2006.	8-K	000-24657	99.1	June 30, 2006
10.4	Employment Agreement between B. Keith Clark and Mannatech, dated August 28, 2006.	8-K	000-24657	99.1	August 29, 2006
10.5*	Renewal of Consulting Agreement between Dr. Bill McAnalley and Mannatech, dated August 15, 2006.	*	*	*	*
31.1*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, of the Chief Executive Officer of Mannatech.	*	*	*	*
31.2*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, of the Chief Financial Officer of Mannatech.	*	*	*	*
32.1*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of the Chief Executive Officer of Mannatech.	*	*	*	*
32.2*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of the Chief Financial Officer of Mannatech.	*	*	*	*

^{*} filed herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MANNATECH, INCORPORATED

November 9, 2006 /S/ SAMUEL L. CASTER

Samuel L. Caster Chief Executive Officer and Chairman of the Board (principal executive officer)

November 9, 2006 /S/ STEPHEN D. FENSTERMACHER

Stephen D. Fenstermacher Senior Vice President and Chief Financial Officer (principal financial officer)

43

INDEX TO EXHIBITS

Incorporated by Reference

Exhibit

Number	Exhibit Description	Form	File No.	Exhibit (s)	Filing Date
3.1	Amended and Restated Articles of Incorporation of Mannatech, dated May 19, 1998.		333-63133	3.1	October 28.1998
3.2	Fourth Amended and Restated Bylaws of Mannatech, dated August 8, 2001.		000-24657	99.1	August 22, 2001
4.1	Specimen Certificate representing Mannatech s common stock, par value \$0.0001 per share.	S-1	333-63133	4.1	October 28, 1998
10.1	Consulting Agreement between Bettina S. Simon and Mannatech, dated June 11, 2006.	8-K	000-24657	99.1	June 12, 2006
10.2	Employment Agreement between Stephen D. Fenstermacher and Mannatech, dated June 15, 2006.	8-K	000-24657	99.1	June 19, 2006
10.3	Employment Agreement between Terence O Day and Mannatech, dated June 27, 2006.	8-K	000-24657	99.1	June 30, 2006
10.4	Employment Agreement between B. Keith Clark and Mannatech, dated August 28, 2006.	8-K	000-24657	99.1	August 29, 2006
10.5*	Renewal of Consulting Agreement between Dr. Bill McAnalley and Mannatech, dated August 15, 2006.	*	*	*	*
31.1*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, of the Chief Executive Officer of Mannatech.	*	*	*	*
31.2*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, of the Chief Financial Officer of Mannatech.	*	*	*	*
32.1*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of the Chief Executive Officer of Mannatech.	*	*	*	*
32.2*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of the Chief Financial Officer of Mannatech.	*	*	*	*

^{*} filed herewith.

1